Header Logo

BORJE S ANDERSSON

TitleProfessor
InstitutionMD Anderson
DepartmentStem Cell Transplantation
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Ramdial J, Lin R, Thall PF, Valdez BC, Hosing C, Srour S, Popat U, Qazilbash M, Alousi A, Barnett M, Gulbis A, Shigle TL, Shpall EJ, Andersson BS, Nieto Y. High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas. Bone Marrow Transplant. 2024 Dec; 59(12):1754-1762. PMID: 39341929; PMCID: PMC11611727.
      Citations:    Fields:    Translation:Humans
    2. Suwantarat N, Iamsirirak P, Chanapai J, Pakakasama S, Andersson BS, Boelens JJ, Anurathapan U, Hongeng S. Desensitization with daratumumab in a pediatric patient with thalassemia major and high donor-specific antibody prior to haploidentical transplantation. Pediatr Blood Cancer. 2024 Nov; 71(11):e31311. PMID: 39228048.
      Citations:    Fields:    Translation:Humans
    3. Valdez BC, Tsimberidou AM, Yuan B, Baysal MA, Chakraborty A, Andersen CR, Andersson BS. Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations. Int J Mol Sci. 2024 Aug 26; 25(17). PMID: 39273190; PMCID: PMC11394699.
      Citations:    Fields:    Translation:HumansCells
    4. Wermke M, Holderried TAW, Luke JJ, Morris VK, Alsdorf WH, Wetzko K, Andersson BS, Wistuba II, Parra ER, Hossain MB, Grund-Gr?schke S, Aslan K, Satelli A, Marisetty A, Satam S, Kalra M, Hukelmann J, Kursunel MA, Pozo K, Acs A, Backert L, Baumeister M, Bunk S, Wagner C, Schoor O, Mohamed AS, Mayer-Mokler A, Hilf N, Krishna D, Walter S, Tsimberidou AM, Britten CM. First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. J Immunother Cancer. 2024 Jul 22; 12(7). PMID: 39038917; PMCID: PMC11268062.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    5. Cao X, Li Z, Zhang Y, Cui Q, Dai H, Ma Y, Li M, Chen S, Yin J, Cui W, Chen J, Sun A, Qiu H, Chen S, Zhu X, Andersson BS, Wu D, Tang X. Chidamide combined with a modified Bu-Cy conditioning regimen improves survival in patients with T-cell acute lymphoblastic leukemia/lymphoma undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2024 Aug; 103(8):3083-3093. PMID: 38900303; PMCID: PMC11283404.
      Citations:    Fields:    Translation:Humans
    6. Valdez BC, Tsimberidou AM, Yuan B, Nieto Y, Baysal MA, Chakraborty A, Andersen CR, Andersson BS. Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy. Oncotarget. 2024 Jun 03; 15:361-373. PMID: 38829622; PMCID: PMC11146633.
      Citations:    Fields:    Translation:HumansCells
    7. Valdez BC, Yuan B, Murray D, Ramdial JL, Popat U, Nieto Y, Andersson BS. ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells. Oncotarget. 2024 Mar 14; 15:220-231. PMID: 38484153; PMCID: PMC10939475.
      Citations:    Fields:    Translation:HumansCells
    8. F?rst S, Bernit E, Legrand F, Granata A, Harbi S, Devillier R, Maisano V, Bouchacourt B, Pagliardini T, Mokart D, Lemari? C, Calmels B, Picard C, Basire A, Andersson BS, Blaise D. Durable engraftment after pharmacological pre-transplant immune suppression followed by reduced-toxicity myeloablative haploidentical stem cell transplantation in highly HLA-immunized adults with sickle cell disease. Bone Marrow Transplant. 2024 Jul; 59(7):918-927. PMID: 38486114.
      Citations:    Fields:    Translation:Humans
    9. Ahmed S, Bashir Q, Bassett RL, Ullah F, Aung F, Valdez BC, Alousi AM, Hosing C, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Rezvani K, Mehta R, Shpall EJ, Ciurea S, Andersson BS, Champlin RE, Popat UR. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. Am J Hematol. 2024 04; 99(4):562-569. PMID: 38314663; PMCID: PMC10947843.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    10. Tsimberidou AM, Baysal MA, Chakraborty A, Andersson BS. Autologous engineered T cell receptor therapy in advanced cancer. Hum Vaccin Immunother. 2023 12 15; 19(3):2290356. PMID: 38114231; PMCID: PMC10732691.
      Citations:    Fields:    Translation:HumansCells
    11. Valdez BC, Yuan B, Murray D, Ramdial JL, Nieto Y, Popat U, Tang X, Andersson BS. Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells. Front Oncol. 2023; 13:1287444. PMID: 38074694; PMCID: PMC10701888.
      Citations: 1     
    12. Bulliard Y, Andersson BS, Baysal MA, Damiano J, Tsimberidou AM. Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy. J Hematol Oncol. 2023 10 25; 16(1):108. PMID: 37880715; PMCID: PMC10601191.
      Citations:    Fields:    Translation:Humans
    13. Popat UR, Pasvolsky O, Bassett R, Mehta RS, Olson A, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Saini N, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. Blood Adv. 2023 10 24; 7(20):6196-6205. PMID: 37611156; PMCID: PMC10582839.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    14. Alkhaldi H, Reinhardt A, Barnett M, Kundu S, Hosing C, Ramdial J, Saini N, Srour S, Alousi A, Kebriaei P, Popat U, Qazilbash M, Champlin R, Shpall EJ, Gulbis A, Shigle TL, Dabaja B, Pinnix C, Ahmed S, Steiner R, Andersson BS, Nieto Y. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Transplant Cell Ther. 2023 Nov; 29(11):690-694. PMID: 37607645.
      Citations:    Fields:    Translation:Humans
    15. Wagner C, Fritsche J, Maurer D, Tsimberidou AM, Guenther K, Andersson BS, Mendrzyk R, Alpert A, Nowak A, Aslan K, Satelli A, Richter F, Kuttruff-Coqui S, Schoor O, Coughlin Z, Mohamed AS, Sieger K, Norris B, Ort R, Beck J, Vo HH, Hoffgaard F, Ruh M, Backert L, Wistuba II, Fuhrmann D, Ibrahim NK, Morris VK, Kee BK, Halperin DM, Nogueras-Gonzalez GM, Kebriaei P, Shpall EJ, Vining D, Hwu P, Singh H, Reinhardt C, Britten CM, Hilf N, Weinschenk T, Walter S. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer. Cancer Immunol Res. 2023 07 05; 11(7):925-945. PMID: 37172100; PMCID: PMC10330623.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    16. Ramdial J, Chan KH, Sanchez Petitto G, Valdez B, Andersson BS, Nieto Y. Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy. Bone Marrow Transplant. 2023 06; 58(6):635-638. PMID: 36966213.
      Citations:    Fields:    Translation:Humans
    17. Ramdial JL, Valdez BC, Andersson BS, Nieto Y. Romidepsin antagonism with CHOEP. Leukemia. 2023 05; 37(5):1160-1161. PMID: 36906714.
      Citations:    Fields:    Translation:Humans
    18. Tannumsaeung S, Anurathapan U, Pakakasama S, Pongpitcha P, Songdej D, Sirachainan N, Andersson BS, Hongeng S. Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders. Eur J Haematol. 2023 Mar; 110(3):305-312. PMID: 36451282.
      Citations:    Fields:    Translation:HumansCells
    19. Valdez BC, Nieto Y, Yuan B, Murray D, Andersson BS. HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs. Oncotarget. 2022 10 14; 13:1122-1135. PMID: 36243940; PMCID: PMC9564514.
      Citations: 1     Fields:    Translation:HumansCells
    20. Popat UR, Andersson BS, Bassett R, Kawedia J, Valdez BC, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Nieto Y, Oran B, Olson A, Qazilbash MH, Srour SA, Shpall EJ, Champlin RE, Mehta RS. A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study. Haematologica. 2022 10 01; 107(10):2496-2500. PMID: 35770531; PMCID: PMC9521225.
      Citations:    Fields:    
    21. Anurathapan U, Pakakasama S, Songdej D, Pongphitcha P, Chuansumrit A, Andersson BS, Hongeng S. Haploidentical Hematopoietic Stem Cell Transplantation in Thalassemia. Hemoglobin. 2022 Jan; 46(1):2-6. PMID: 35920292.
      Citations:    
    22. Andersson BS, Thall PF, Ma J, Valdez BC, Bassett R, Chen J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Gulbis A, Cool R, Kawedia J, Hosing C, Kebriaei P, Kornblau S, Myers A, Oran B, Rezvani K, Shah N, Shpall E, Parmar S, Popat UR, Nieto Y, Champlin RE. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan???clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant. 2022 08; 57(8):1295-1303. PMID: 35610308; PMCID: PMC9352570.
      Citations:    Fields:    
    23. Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica. 2022 04 01; 107(4):899-908. PMID: 33951890; PMCID: PMC8968895.
      Citations: 1     Fields:    Translation:Humans
    24. Valdez BC, Yuan B, Murray D, Nieto Y, Popat U, Andersson BS. Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. Leuk Lymphoma. 2022 07; 63(7):1634-1644. PMID: 35188042.
      Citations:    Fields:    Translation:HumansCells
    25. Valdez BC, Murray D, Yuan B, Nieto Y, Popat U, Andersson BS. ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells. Oncotarget. 2022; 13:319-330. PMID: 35154579; PMCID: PMC8830224.
      Citations:    Fields:    
    26. Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther. 2021 11; 27(11):913.e1-913.e12. PMID: 34329753.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    27. Tsimberidou AM, Van Morris K, Vo HH, Eck S, Lin YF, Rivas JM, Andersson BS. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. J Hematol Oncol. 2021 06 30; 14(1):102. PMID: 34193217; PMCID: PMC8243554.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    28. Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol. 2021 08 20; 39(24):2710-2719. PMID: 33929874; PMCID: PMC10166368.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    29. Ramdial JL, Mehta RS, Saliba RM, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Andersson BS, Champlin RE, Popat U. Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. Bone Marrow Transplant. 2021 08; 56(8):2005-2012. PMID: 33846563.
      Citations:    Fields:    Translation:Humans
    30. Tang X, Valdez BC, Ma Y, Zhang Q, Qu C, Dai H, Yin J, Li Z, Xu T, Xu Y, Chen J, Zhu X, Chen Z, Wu D, Andersson BS. Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2021 07; 56(7):1674-1682. PMID: 33637882.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    31. Joseph J, Ma J, Hennawy F, Abdulrazzaq MN, Saini N, Patel RD, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Srour S, Kebriaei P, Bashir Q, Nastoupil LJ, Westin JR, Rondon G, Champlin RE, Andersson BS, Nieto Y, Muzzafar T, Ahmed S. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2021 05; 27(5):404.e1-404.e5. PMID: 33965178.
      Citations:    Fields:    Translation:Humans
    32. Ahmed S, Bashir Q, Bassett R, Poon MC, Valdez B, Konoplev S, Alousi AM, Andersson BS, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Kim S, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin R, Popat U. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther. 2021 05; 27(5):430.e1-430.e7. PMID: 33965187.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    33. Saliba RM, Mehta RS, Alousi AM, Marin D, Valdez BC, Chen J, Bashir Q, Ciurea SO, Olson AL, Hosing C, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Andersson BS, Popat UR, Oran B. Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2021 05 15; 127(10):1598-1605. PMID: 33471943.
      Citations:    Fields:    Translation:Humans
    34. Andersson BS, de Lima M, Esteves I, Santos FPS, Ribeiro AAF, Seber A, Sugawara EK, Sobrinho JJDN, Barros JC, Oliveira JSR, Fernandes JF, Hamerschlak N, Kerbauy FR. Targeted-dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 ?Mol?min. A historically controlled clinical trial. Hematol Oncol. 2020 Dec; 38(5):773-781. PMID: 32779746.
      Citations: 2     Fields:    Translation:Humans
    35. Prasongtanakij S, Anurathapan U, Vanichapol T, Jittorntrum B, Atjanasuppat K, Pongpitcha P, Pakakasama S, Songdej D, Sirachainan N, Paisooksantivatana K, Borwaornpinyo S, Andersson BS, Hongeng S. Production and characterization of haploidentical CD19 CAR T cells: Validated to induce a continuous complete remission in a patient with relapsed refractory B-cell ALL. Asia Pac J Clin Oncol. 2022 Feb; 18(1):44-51. PMID: 32970928.
      Citations: 1     Fields:    Translation:HumansCells
    36. Abudayyeh A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Martinez CS, Page VD, Tarrand JJ, Kontoyiannis DP, Marin D, Oran B, Olson A, Jones R, Popat U, Champlin RE, Chemaly RF, Shpall EJ, Rezvani K. Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients. Transpl Infect Dis. 2020 Oct; 22(5):e13395. PMID: 32602954.
      Citations:    Fields:    Translation:HumansCells
    37. Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol. 2021; 144(1):74-81. PMID: 32604096.
      Citations: 1     Fields:    Translation:Humans
    38. Kawedia JD, Handy VW, Shigle TL, Gulbis AM, Nieto Y, Andersson BS. Letter to the Editor Regarding "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". Biol Blood Marrow Transplant. 2020 09; 26(9):e232-e234. PMID: 32407883.
      Citations:    Fields:    Translation:Humans
    39. Popat U, Mehta RS, Bassett R, Kongtim P, Chen J, Alousi AM, Anderlini P, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Lindsay R, Nieto Y, Olson A, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson BS, Champlin RE. Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant. 2020 08; 26(8):1439-1445. PMID: 32438043; PMCID: PMC7547798.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    40. Varma A, Abraham SC, Mehta RS, Saini NY, Honhar M, Rashid M, Chen J, Srour SA, Bashir Q, Rondon G, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Anderlini P, Andersson BS, Shpall EJ, Champlin RE, Popat UR. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv. 2020 04 14; 4(7):1296-1306. PMID: 32236526; PMCID: PMC7160275.
      Citations: 1     Fields:    Translation:Humans
    41. Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Bashir Q, Qazilbash MH, Andersson BS. Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells. Exp Hematol. 2020 01; 81:32-41. PMID: 31954171; PMCID: PMC7023992.
      Citations: 3     Fields:    Translation:HumansCells
    42. Anurathapan U, Hongeng S, Pakakasama S, Songdej D, Sirachainan N, Pongphitcha P, Chuansumrit A, Charoenkwan P, Jetsrisuparb A, Sanpakit K, Rujkijyanont P, Meekaewkunchorn A, Lektrakul Y, Iamsirirak P, Surapolchai P, Sirireung S, Sruamsiri R, Wahidiyat PA, Andersson BS. Hematopoietic Stem Cell Transplantation for Severe Thalassemia Patients from Haploidentical Donors Using a Novel Conditioning Regimen. Biol Blood Marrow Transplant. 2020 06; 26(6):1106-1112. PMID: 31931116.
      Citations: 13     Fields:    Translation:Humans
    43. Apiwattanakul N, Hongeng S, Anurathapan U, Pakakasama S, Srisala S, Klinmalai C, Andersson BS. CMV-Reactive NK Cells in Pediatric Post-Hematopoietic Stem Cell Transplant. Transplant Proc. 2020 Jan - Feb; 52(1):353-359. PMID: 31870602.
      Citations:    Fields:    Translation:HumansCells
    44. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. Haematologica. 2019 12; 104(12):e555-e557. PMID: 30948491; PMCID: PMC6959196.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    45. Kawedia JD, Kalariya N, Gulbis AM, Andersson BS, Myers AL. Pharmacokinetics: Unique Challenges in Blood Monitoring for Oncology Nurses. Clin J Oncol Nurs. 2019 04 01; 23(2):191-196. PMID: 30880803.
      Citations: 1     Fields:    Translation:Humans
    46. Bashir Q, Thall PF, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH, Milton DR. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019 May; 6(5):e266-e275. PMID: 30910541; PMCID: PMC9446704.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    47. Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing C, Ciurea S, Andersson B, Shpall E, Champlin R, Srour SA, Qazilbash MH. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant. 2019 05; 25(5):1039-1044. PMID: 30639822; PMCID: PMC7053532.
      Citations: 6     Fields:    Translation:Humans
    48. Xu Y, Thall PF, Hua W, Andersson BS. Bayesian non-parametric survival regression for optimizing precision dosing of intravenous busulfan in allogeneic stem cell transplantation. J R Stat Soc Ser C Appl Stat. 2019 Apr; 68(3):809-828. PMID: 31467455; PMCID: PMC6714050.
      Citations: 1     
    49. Alatrash G, Kidwell KM, Thall PF, Di Stasi A, Chen J, Zope M, Crain AK, Champlin RE, Popat U, Shpall EJ, Jones RB, Andersson BS. Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. Bone Marrow Transplant. 2019 08; 54(8):1245-1253. PMID: 30532055; PMCID: PMC6557700.
      Citations: 2     Fields:    Translation:Humans
    50. Kellner JN, Delemarre EM, Yvon E, Nierkens S, Boelens JJ, McNiece I, Olson A, Nieto Y, Ciurea S, Popat U, Ahmed S, Champlin R, Ramos J, Nishimoto M, Ma H, Ke Z, Thall P, Khoury JD, Negrin R, Andersson B, Parmar S. Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. Oncotarget. 2018 Nov 02; 9(86):35611-35622. PMID: 30479692; PMCID: PMC6235025.
      Citations: 11     Fields:    
    51. Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol. 2018 Nov; 5(11):e532-e542. PMID: 30389035; PMCID: PMC6317874.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    52. Pou C, Barrientos-Somarribas M, Marin-Juan S, Bogdanovic G, Bjerkner A, Allander T, Gustafsson B, Andersson B. Virome definition in cerebrospinal fluid of patients with neurological complications after hematopoietic stem cell transplantation. J Clin Virol. 2018 11; 108:112-120. PMID: 30296744.
      Citations: 2     Fields:    Translation:HumansCells
    53. Kongtim P, Parmar S, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SO, Milton DR. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2019 06; 54(6):839-848. PMID: 30258129; PMCID: PMC7285649.
      Citations: 8     Fields:    Translation:Humans
    54. Valdez BC, Tang X, Li Y, Murray D, Liu Y, Popat U, Champlin RE, Andersson BS. Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells. Exp Hematol. 2018 11; 67:49-59.e1. PMID: 30102945; PMCID: PMC6262883.
      Citations: 2     Fields:    Translation:HumansCells
    55. Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2018 08; 24(8):1602-1609. PMID: 29501779; PMCID: PMC8212703.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    56. Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2018 07; 24(7):1514-1520. PMID: 29448058.
      Citations: 22     Fields:    Translation:Humans
    57. Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K, Oran B. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood. 2018 03 15; 131(11):1248-1257. PMID: 29386198; PMCID: PMC6031309.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    58. Tamari R, Oran B, Hilden P, Maloy M, Kongtim P, Papadopoulos EB, Rondon G, Jakubowski AA, Andersson BS, Devlin SM, Ahmed S, Popat UR, Ponce D, Chen J, Sauter C, Young JW, de Lima M, Perales MA, O'Reilly RJ, Giralt SA, Champlin RE, Castro-Malaspina H. Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 05; 24(5):1079-1087. PMID: 29325829; PMCID: PMC6529210.
      Citations: 7     Fields:    Translation:Humans
    59. Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS. Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells. Oncotarget. 2018 Jan 09; 9(3):3908-3921. PMID: 29423093; PMCID: PMC5790510.
      Citations: 23     Fields:    
    60. Andersson BS, Apiwattanakul N, Hongeng S, Anurathapan U, Pakakasama S, Srisala S, Techasaensiri C. Viral-specific T-cell response in hemorrhagic cystitis after haploidentical donor stem cell transplantation. Transpl Infect Dis. 2017 Dec; 19(6). PMID: 28865164.
      Citations: 3     Fields:    Translation:HumansCells
    61. Myers AL, Kawedia JD, Champlin RE, Kramer MA, Nieto Y, Ghose R, Andersson BS. Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. Expert Opin Drug Metab Toxicol. 2017 Sep; 13(9):901-923. PMID: 28766962; PMCID: PMC5584057.
      Citations: 24     Fields:    Translation:HumansAnimals
    62. Huang XJ, Liu K, Ritchie D, Andersson B, Lu J, Hou J, Burguera AF, Wang J, Yeoh A, Yan C, Zhou D, Tan D, Kim DW, Wu D, Shpall E, Kornblau S, Neelapu S, Hongeng S, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Hagemeister F, Westin J, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Orlowski RZ, Chim CS, Mulligan S, Sanz M, Ozawa K, Parmar S, Issaragrisil S. Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget. 2017 Jun 20; 8(25):41620-41630. PMID: 28404929; PMCID: PMC5522281.
      Citations: 1     Fields:    Translation:Humans
    63. Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol. 2017 Jun; 4(6):e283-e292. PMID: 28522110; PMCID: PMC5844223.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    64. Valdez BC, Hassan M, Andersson BS. Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions. Exp Hematol. 2017 08; 52:65-71. PMID: 28479418; PMCID: PMC5522632.
      Citations: 2     Fields:    Translation:HumansCells
    65. Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS. The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. Leuk Lymphoma. 2017 11; 58(11):2705-2716. PMID: 28394191; PMCID: PMC5526721.
      Citations: 4     Fields:    Translation:HumansCells
    66. Kreetapirom P, Hongeng S, Manuyakorn W, Anurathapan U, Pakakasama S, Sirachainan N, Andersson BS. Successful HLA haploidentical HSCT with post-transplant cyclophosphamide in Wiskott-Aldrich syndrome. Bone Marrow Transplant. 2017 06; 52(6):913-914. PMID: 28287640.
      Citations: 2     Fields:    Translation:Humans
    67. Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol. 2017 Apr; 92(4):331-337. PMID: 28052408; PMCID: PMC5352512.
      Citations: 19     Fields:    Translation:Humans
    68. Kanakry CG, Kasamon YL, Zahurak M, Durakovic N, Furlong T, Mielcarek M, Medeot M, Gojo I, Smith BD, Kanakry JA, Borrello IM, Brodsky RA, Gladstone DE, Huff CA, Matsui WH, Swinnen LJ, Cooke KR, Ambinder RF, Fuchs EJ, de Lima MJ, Andersson BS, Varadhan R, O'Donnell PV, Jones RJ, Luznik L, Bola?os-Meade J. Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood. 2017 03 09; 129(10):1389-1393. PMID: 28049637; PMCID: PMC5345732.
      Citations: 26     Fields:    Translation:Humans
    69. Abudayyeh A, Hamdi A, Abdelrahim M, Lin H, Page VD, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Oran B, Chemaly RF, Ahmed S, Abudayyeh I, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Rezvani K. Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transpl Infect Dis. 2017 Feb; 19(1). PMID: 27862740.
      Citations: 4     Fields:    Translation:HumansCells
    70. Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplant. 2017 Apr; 52(4):580-587. PMID: 27991894; PMCID: PMC5382042.
      Citations: 20     Fields:    Translation:Humans
    71. Alsuliman A, Muftuoglu M, Khoder A, Ahn YO, Basar R, Verneris MR, Muranski P, Barrett AJ, Liu E, Li L, Stringaris K, Armstrong-James D, Shaim H, Kondo K, Imahashi N, Andersson B, Marin D, Champlin RE, Shpall EJ, Rezvani K. A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. Blood. 2017 02 09; 129(6):740-758. PMID: 27821506; PMCID: PMC5301823.
      Citations: 14     Fields:    Translation:HumansCells
    72. Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant. 2017 Feb; 23(2):285-292. PMID: 27816651; PMCID: PMC5926804.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    73. Valdez BC, Li Y, Murray D, Brammer JE, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget. 2016 Sep 27; 7(39):63829-63838. PMID: 27564097; PMCID: PMC5325407.
      Citations: 6     Fields:    Translation:HumansCells
    74. Bogdanovic G, Pou C, Barrientos-Somarribas M, Bjerkner A, Allander T, Andersson B, Gustafsson B, Honkaniemi E. Virome characterisation from Guthrie cards in children who later developed acute lymphoblastic leukaemia. Br J Cancer. 2016 10 11; 115(8):1008-1014. PMID: 27552439; PMCID: PMC5061901.
      Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
    75. Jorgensen JL, Marin D, Wang S, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Bassett R, Lyons G, Chen J, Rezvani K, Popat U, Kebriaei P, Patel K, Rondon G, Shpall EJ, Champlin RE, Oran B. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica. 2017 01; 102(1):110-117. PMID: 27540139; PMCID: PMC5210241.
      Citations: 16     Fields:    Translation:Humans
    76. Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS. Long-Term Outcomes after Treatment with Clofarabine???Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2016 10; 22(10):1792-1800. PMID: 27377901; PMCID: PMC5026955.
      Citations: 6     Fields:    Translation:Humans
    77. Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 2016 07 14; 128(2):297-312. PMID: 27247137; PMCID: PMC4946205.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    78. Valdez BC, Brammer JE, Li Y, Murray D, Teo EC, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. Leuk Res. 2016 08; 47:100-8. PMID: 27294334; PMCID: PMC4961533.
      Citations: 2     Fields:    Translation:HumansCells
    79. Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016 09 01; 122(17):2680-8. PMID: 27203405; PMCID: PMC4992444.
      Citations: 18     Fields:    Translation:Humans
    80. Andersson BS, Valdez BC. Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect? Bone Marrow Transplant. 2016 07; 51(7):919-20. PMID: 27111045.
      Citations: 1     Fields:    Translation:Humans
    81. Cortes J, Beitinjaneh A, Chen HC, de Lima M, Patel K, Ravandi F, Wang X, Brandt M, Andersson BS, Ciurea S, Santos FP, de Padua Silva L, Shpall EJ, Champlin RE, Kantarjian H, Borthakur G, Oran B. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biol Blood Marrow Transplant. 2016 07; 22(7):1218-1226. PMID: 27058617; PMCID: PMC6201699.
      Citations: 26     Fields:    Translation:HumansCells
    82. Teo EC, Valdez BC, Ji J, Li Y, Liu Y, Brammer JE, Hosing C, Nieto Y, Champlin RE, Andersson BS. Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. Leuk Lymphoma. 2016 11; 57(11):2644-52. PMID: 26980288; PMCID: PMC8489015.
      Citations: 4     Fields:    Translation:HumansCells
    83. Ji J, Valdez BC, Li Y, Liu Y, Teo EC, Nieto Y, Champlin RE, Andersson BS. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study. Exp Hematol. 2016 06; 44(6):458-65. PMID: 26976752; PMCID: PMC4864055.
      Citations: 3     Fields:    Translation:HumansCells
    84. Abudayyeh A, Hamdi A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Salahudeen A, Oran B, Chemaly RF, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Winkelmayer WC, Rezvani K. Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. Am J Transplant. 2016 05; 16(5):1492-502. PMID: 26608093; PMCID: PMC5653306.
      Citations: 13     Fields:    Translation:HumansCells
    85. Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Shpall EJ, Champlin RE, Popat U. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant. 2016 May; 22(5):961-5. PMID: 26921820; PMCID: PMC7176024.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    86. Anurathapan U, Hongeng S, Pakakasama S, Sirachainan N, Songdej D, Chuansumrit A, Charoenkwan P, Jetsrisuparb A, Sanpakit K, Rujkijyanont P, Meekaewkunchorn A, Lektrakul Y, Iamsirirak P, Surapolchai P, Satayasai W, Sirireung S, Sruamsiri R, Wahidiyat PA, Ungkanont A, Issaragrisil S, Andersson BS. Hematopoietic stem cell transplantation for homozygous ?-thalassemia and ?-thalassemia/hemoglobin E patients from haploidentical donors. Bone Marrow Transplant. 2016 Jun; 51(6):813-8. PMID: 26878659; PMCID: PMC4957689.
      Citations: 24     Fields:    Translation:Humans
    87. Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L, SCHEDULE investigators, R?degran G. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study. Am J Transplant. 2016 Apr; 16(4):1238-47. PMID: 26820618.
      Citations: 17     Fields:    Translation:Humans
    88. Andersson BS. Fludarabine-IV busulfan, dose-intensity and progression-free survival: Are we finally finding the way to reach a consensus opinion?: Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the acute leukemia working party of the European group for blood and marrow transplantation. Leuk Res. 2016 Feb; 41:5-6. PMID: 26733443.
      Citations:    Fields:    Translation:Humans
    89. Wang Y, Yang F, Shen Y, Zhang W, Wang J, Chang VT, Andersson BS, Qazilbash MH, Champlin RE, Berenson JR, Guan X, Wang ML. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. J Natl Cancer Inst. 2016 Mar; 108(3). PMID: 26582244; PMCID: PMC6280981.
      Citations: 15     Fields:    Translation:Humans
    90. Valdez BC, Brammer JE, Li Y, Murray D, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer J. 2015 Oct 16; 5:e357. PMID: 26473529; PMCID: PMC4635192.
      Citations: 26     Fields:    Translation:HumansCells
    91. Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for?Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. 2016 Jan; 22(1):47-53. PMID: 26343946; PMCID: PMC4892364.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    92. Lee HC, Saliba RM, Rondon G, Chen J, Charafeddine Y, Medeiros LJ, Alatrash G, Andersson BS, Popat U, Kebriaei P, Ciurea S, Oran B, Shpall E, Champlin R. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of?Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1948-54. PMID: 26183077; PMCID: PMC4604040.
      Citations: 24     Fields:    Translation:HumansCells
    93. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1914-20. PMID: 26071868; PMCID: PMC4781754.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    94. Jimenez AM, De Lima M, Popat UR, Bassett R, Andersson B, Borthakur G, Bashir Q, Chen J, Ciurea SO, Jabbour E, Cortes J, Kebriaei P, Khouri IF, Qazilbash MH, Ravandi F, Rondon G, Lu X, Shpall EJ, Champlin RE, Oran B. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1405-1412. PMID: 25840338; PMCID: PMC4506709.
      Citations: 10     Fields:    Translation:Humans
    95. Arora S, Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Gude E, Ioanes D, Solbu D, Sigurdardottir V, Dellgren G, Erikstad I, Solberg OG, Ueland T, Aukrust P, Gullestad L, SCHEDULE (SCandinavian HEart transplant everolimus De novo stUdy with earLy calcineurin inhibitors a, B?tker HE, R?degran G. The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial. Am J Transplant. 2015 Jul; 15(7):1967-75. PMID: 25783974.
      Citations: 13     Fields:    Translation:Humans
    96. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92. PMID: 25778529; PMCID: PMC4424412.
      Citations: 50     Fields:    Translation:HumansCells
    97. Valdez BC, Li Y, Murray D, Ji J, Liu Y, Popat U, Champlin RE, Andersson BS. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators. Exp Hematol. 2015 Jun; 43(6):448-61.e2. PMID: 25704054; PMCID: PMC4458397.
      Citations: 6     Fields:    Translation:HumansCells
    98. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant. 2015 May; 21(5):906-12. PMID: 25667989; PMCID: PMC4825327.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    99. Kongtim P, Di Stasi A, Rondon G, Chen J, Adekola K, Popat U, Oran B, Kebriaei P, Andersson BS, Champlin RE, Ciurea SO. Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation? Biol Blood Marrow Transplant. 2015 Apr; 21(4):713-9. PMID: 25540936; PMCID: PMC4359638.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    100. Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, Mielcarek M, Champlin RE, Jones RJ, Thall PF, Andersson BS, Luznik L. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014 Nov 01; 32(31):3497-505. PMID: 25267759; PMCID: PMC4209101.
      Citations: 95     Fields:    Translation:HumansCTClinical Trials
    101. Song G, Valdez BC, Li Y, Liu Y, Champlin RE, Andersson BS. Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1687-95. PMID: 25111583; PMCID: PMC5002996.
      Citations: 6     Fields:    Translation:HumansCells
    102. Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E, Jansson K, Solbu D, Sigurdardottir V, Arora S, Dellgren G, Gullestad L, SCHEDULE Investigators. Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant. 2014 Aug; 14(8):1828-38. PMID: 25041227.
      Citations: 21     Fields:    Translation:Humans
    103. Anurathapan U, Pakakasama S, Mekjaruskul P, Sirachainan N, Songdej D, Chuansumrit A, Charoenkwan P, Jetsrisuparb A, Sanpakit K, Pongtanakul B, Rujkijyanont P, Meekaewkunchorn A, Sruamsiri R, Ungkanont A, Issaragrisil S, Andersson BS, Hongeng S. Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2066-71. PMID: 25064743; PMCID: PMC5538782.
      Citations: 16     Fields:    Translation:Humans
    104. Oran B, Kongtim P, Popat U, de Lima M, Jabbour E, Lu X, Chen J, Rondon G, Kebriaei P, Ahmed S, Andersson B, Alousi A, Ciurea S, Shpall E, Champlin RE. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1618-25. PMID: 24953017; PMCID: PMC6201698.
      Citations: 19     Fields:    Translation:HumansCells
    105. Tang X, Alatrash G, Ning J, Jakher H, Stafford P, Zope M, Shpall EJ, Jones RB, Champlin RE, Thall PF, Andersson BS. Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1139-44. PMID: 24727332; PMCID: PMC4099297.
      Citations: 10     Fields:    Translation:Humans
    106. Song G, Valdez BC, Li Y, Dominguez JR, Corn P, Champlin RE, Andersson BS. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leuk Lymphoma. 2014 Jul; 55(7):1625-34. PMID: 24144307; PMCID: PMC4320642.
      Citations: 5     Fields:    Translation:HumansCells
    107. Helmersson S, Ivarsson S, Johansson C, Henriques-Normark B, Lopez-Valladares G, Tham W, Parihar VS, Andersson B, Ringberg H, Tjernberg I, Danielsson-Tham ML. Human isolates of Listeria monocytogenes in Sweden during half a century (1958-2010). Epidemiol Infect. 2014 Nov; 142(11):2251-60. PMID: 24480252; PMCID: PMC9151308.
      Citations: 7     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    108. Valdez BC, Zander AR, Song G, Murray D, Nieto Y, Li Y, Champlin RE, Andersson BS. Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines. Blood Cancer J. 2014 Jan 10; 4:e171. PMID: 24413065; PMCID: PMC3913938.
      Citations: 8     Fields:    
    109. Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ. The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):e1-5. PMID: 24169268; PMCID: PMC3913126.
      Citations: 8     Fields:    Translation:HumansCells
    110. Oran B, Popat U, Andersson B, Champlin R. Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S282-8. PMID: 24290213.
      Citations: 4     Fields:    Translation:Humans
    111. Anurathapan U, Pakakasama S, Rujkijyanont P, Sirachainan N, Songdej D, Chuansumrit A, Sirireung S, Charoenkwan P, Jetsrisuparb A, Issaragrisil S, Ungkanont A, Sruamsiri R, Srisala S, Andersson BS, Hongeng S. Pretransplant immunosuppression followed by reduced-toxicity conditioning and stem cell transplantation in high-risk thalassemia: a safe approach to disease control. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1259-62. PMID: 23648235; PMCID: PMC4429773.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    112. Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. Exp Hematol. 2013 Aug; 41(8):719-30. PMID: 23648290; PMCID: PMC3769691.
      Citations: 8     Fields:    Translation:HumansCells
    113. Nilsson J, Andersson R, Andersson B, Spelt L. Artificial neural networks--a method for prediction of survival following liver resection for colorectal cancer metastases. Eur J Surg Oncol. 2013 Jun; 39(6):648-54. PMID: 23514791.
      Citations: 19     Fields:    Translation:Humans
    114. Karuturi M, Hosing C, Fanale M, Medeiros LJ, Alousi AM, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson BS, Champlin R, Anderlini P, Popat U. High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma. Biol Blood Marrow Transplant. 2013 Jun; 19(6):991-4. PMID: 23507470; PMCID: PMC4411554.
      Citations: 5     Fields:    Translation:Humans
    115. Bayraktar UD, de Lima M, Saliba RM, Maloy M, Castro-Malaspina HR, Chen J, Rondon G, Chiattone A, Jakubowski AA, Boulad F, Kernan NA, O'Reilly RJ, Champlin RE, Giralt S, Andersson BS, Papadopoulos EB. Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2013 Jun; 19(6):898-903. PMID: 23467126; PMCID: PMC4059063.
      Citations: 45     Fields:    Translation:HumansCells
    116. Hassan M, Andersson BS. Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. Pharmacogenomics. 2013 Jan; 14(1):75-87. PMID: 23252950.
      Citations: 24     Fields:    Translation:HumansAnimals
    117. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012 Dec 13; 367(24):2305-15. PMID: 23234514; PMCID: PMC3805360.
      Citations: 184     Fields:    Translation:HumansCellsCTClinical Trials
    118. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant. 2013 Mar; 19(3):410-7. PMID: 23128322; PMCID: PMC4077191.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    119. Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima M. Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission. Biol Blood Marrow Transplant. 2013 Feb; 19(2):214-20. PMID: 22982533; PMCID: PMC4106407.
      Citations: 10     Fields:    Translation:Humans
    120. Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, Hosing C, Khouri I, Qazilbash M, Popat U, Alousi A, Nieto Y, Jones RB, de Lima M, Champlin RE, Andersson BS. Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1819-26. PMID: 22750645; PMCID: PMC4319530.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    121. Kebriaei P, Madden T, Wang X, Thall PF, Ledesma C, de Lima M, Shpall EJ, Hosing C, Qazilbash M, Popat U, Alousi A, Nieto Y, Champlin RE, Jones RB, Andersson BS. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplant. 2013 Jan; 48(1):26-31. PMID: 22732703; PMCID: PMC4346146.
      Citations: 4     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    122. Valdez BC, Nieto Y, Murray D, Li Y, Wang G, Champlin RE, Andersson BS. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Exp Hematol. 2012 Oct; 40(10):800-10. PMID: 22687754; PMCID: PMC3447105.
      Citations: 21     Fields:    Translation:HumansCells
    123. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1677-86. PMID: 22643322; PMCID: PMC4010147.
      Citations: 20     Fields:    Translation:Humans
    124. Mossberg N, Nordin M, Movitz C, Nilsson S, Hellstrand K, Andersson B, Andersen O, Bergstr?m T. The recurrent Guillain-Barr? syndrome: a long-term population-based study. Acta Neurol Scand. 2012 Sep; 126(3):154-61. PMID: 22507178.
      Citations: 5     Fields:    Translation:Humans
    125. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Ledesma C, Andersson BS, Jones R, Popat UR, Hosing CM, Nieto Y, Qazilbash MH, Ueno NT, Giralt SA, de Lima MJ, Champlin RE. Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. Leuk Lymphoma. 2012 Jun; 53(6):1239-41. PMID: 22132837; PMCID: PMC4493857.
      Citations: 4     Fields:    Translation:Humans
    126. Valdez BC, Murray D, Nieto Y, Li Y, Wang G, Champlin RE, Andersson BS. Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines. Leuk Lymphoma. 2012 May; 53(5):973-81. PMID: 22023523; PMCID: PMC3867126.
      Citations: 11     Fields:    Translation:HumansCells
    127. Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, Andersson BS, Champlin R, Couriel DR. Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol. 2011; 2011:601953. PMID: 22110505; PMCID: PMC3216266.
      Citations: 58     
    128. Kebriaei P, Saliba R, Rondon G, Chiattone A, Luthra R, Anderlini P, Andersson B, Shpall E, Popat U, Jones R, Worth L, Ravandi F, Thomas D, O'Brien S, Kantarjian H, de Lima M, Giralt S, Champlin R. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2012 Apr; 18(4):584-92. PMID: 21867666; PMCID: PMC4102408.
      Citations: 29     Fields:    Translation:HumansCells
    129. Gulbis AM, Culotta KS, Jones RB, Andersson BS. Busulfan and metronidazole: an often forgotten but significant drug interaction. Ann Pharmacother. 2011 Jul; 45(7-8):e39. PMID: 21730282.
      Citations: 8     Fields:    Translation:HumansCells
    130. Wernerman J, Kirketeig T, Andersson B, Berthelson H, Ersson A, Friberg H, Guttormsen AB, Hendrikx S, Rossi P, Scandinavian Critical Care Trials Group, Pettil? V, Sj?berg F, Wins? O. Scandinavian glutamine trial: a pragmatic multi-centre randomised clinical trial of intensive care unit patients. Acta Anaesthesiol Scand. 2011 Aug; 55(7):812-8. PMID: 21658010.
      Citations: 29     Fields:    Translation:Humans
    131. Yang H, Robinson SN, Nieto Y, Jones RJ, Gocke CD, Lu J, Giralt SA, Jones RB, Decker WK, Xing D, Steiner D, Champlin RE, McMannis JD, Ng J, Thomas MW, Shah N, Andersson BS, Parmar S, Shpall EJ. Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma. Cancer Res. 2011 Jul 15; 71(14):5040-9. PMID: 21646477.
      Citations: 9     Fields:    Translation:HumansCells
    132. Alatrash G, Pelosini M, Saliba RM, Koca E, Rondon G, Andersson BS, Chiattone A, Zhang W, Giralt SA, Cernosek AM, Kebriaei P, Alousi AM, Popat UR, Hosing C, Khouri IF, Champlin RE, de Lima MJ. Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1841-5. PMID: 21684343; PMCID: PMC4061975.
      Citations: 9     Fields:    Translation:HumansCells
    133. Champlin R, Jabbour E, Kebriaei P, Anderlini P, Andersson B, de Lima M. Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S96-100. PMID: 22035758; PMCID: PMC3226776.
      Citations: 1     Fields:    Translation:Humans
    134. Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SA. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant. 2012 Feb; 47(2):212-6. PMID: 21423123; PMCID: PMC4320641.
      Citations: 12     Fields:    Translation:Humans
    135. Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant. 2011 Oct; 17(10):1490-6. PMID: 21338705; PMCID: PMC4261630.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    136. Parmar S, Andersson BS, Couriel D, Munsell MF, Fernandez-Vina M, Jones RB, Shpall EJ, Popat U, Anderlini P, Giralt S, Alousi A, Cano P, Bosque D, Hosing C, Silva Lde P, Westmoreland M, Wathen JK, Berry D, Champlin RE, de Lima MJ. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol. 2011 Jan 20; 29(3):294-302. PMID: 21149654; PMCID: PMC3056464.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    137. Bashir Q, Andersson BS, Fernandez-Vina M, de Padua Silva L, Giralt S, Chiattone A, Wei W, Sharma M, Anderlini P, Shpall EJ, Popat U, Rodrigues M, Champlin RE, de Lima M. Unrelated donor transplantation for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2011 Jul; 17(7):1067-71. PMID: 21087679; PMCID: PMC4080632.
      Citations: 3     Fields:    Translation:HumansCells
    138. Cutler C, Kesselheim A, Gabardi S, Andersson BS, Carpenter P, Khoury HJ, Litzow M, Rowley SD, Lanum S, Leather H, Tina Shih YC, Gale RP, Wingard JR, Appelbaum FR, Anasetti C, American Society of Blood and Marrow Transplantation. Generic immunosuppressants in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011 Mar; 17(3):285-90. PMID: 21087678.
      Citations: 3     Fields:    Translation:Humans
    139. Andersson BS. Advances in CML: The role of allogeneic hematopoietic stem cell transplantation. Clin Adv Hematol Oncol. 2010 Nov; 8(11):746-8. PMID: 21326152.
      Citations: 1     Fields:    Translation:Humans
    140. Ciurea SO, Saliba RM, Rondon G, Patah PA, Aung F, Cano P, Andersson BS, Kebriaei P, Popat U, Fernandez-Vina M, Champlin RE, de Lima M. Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 loci. Biol Blood Marrow Transplant. 2011 Jun; 17(6):923-9. PMID: 20969970; PMCID: PMC4112359.
      Citations: 6     Fields:    Translation:Humans
    141. Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE. Clofarabine ? fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant. 2011 Jun; 17(6):893-900. PMID: 20946966; PMCID: PMC3760472.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    142. Valdez BC, Li Y, Murray D, Champlin RE, Andersson BS. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochem Pharmacol. 2011 Jan 15; 81(2):222-32. PMID: 20933509; PMCID: PMC3006064.
      Citations: 23     Fields:    Translation:HumansCells
    143. Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant. 2011 Mar; 17(3):412-20. PMID: 20674757; PMCID: PMC4031688.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    144. Valdez BC, Andersson BS. Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies. Environ Mol Mutagen. 2010 Jul; 51(6):659-68. PMID: 20577993; PMCID: PMC4346159.
      Citations: 20     Fields:    Translation:Humans
    145. Ciurea SO, de Lima M, Giralt S, Saliba R, Bueso-Ramos C, Andersson BS, Hosing CM, Verstovsek S, Champlin RE, Popat U. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant. 2010 Apr; 16(4):555-9. PMID: 20005966; PMCID: PMC4352934.
      Citations: 13     Fields:    Translation:Humans
    146. Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B, Khouri I, Hosing C, Ippoliti C, Shpall EJ, Champlin R, Alousi A. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009 Dec; 15(12):1555-62. PMID: 19896079; PMCID: PMC4114035.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    147. Valdez BC, Li Y, Murray D, Corn P, Champlin RE, Andersson BS. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res. 2010 Mar; 34(3):364-72. PMID: 19732952; PMCID: PMC2823987.
      Citations: 19     Fields:    Translation:HumansCells
    148. Shannon VR, Andersson BS, Lei X, Champlin RE, Kontoyiannis DP. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010 Apr; 45(4):647-55. PMID: 19684637.
      Citations: 54     Fields:    Translation:Humans
    149. Andersson BS, de Lima M, Thall PF, Madden T, Russell JA, Champlin RE. Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia. Curr Opin Oncol. 2009 Jun; 21 Suppl 1:S11-5. PMID: 19561406; PMCID: PMC4037323.
      Citations: 6     Fields:    Translation:HumansAnimals
    150. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S, K?rbling M. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jun; 15(6):718-23. PMID: 19450756; PMCID: PMC4352933.
      Citations: 39     Fields:    Translation:Humans
    151. Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009 May; 15(5):523-36. PMID: 19361744; PMCID: PMC4261695.
      Citations: 59     Fields:    Translation:Humans
    152. Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S, Cort?s JE. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S261-5. PMID: 19778850.
      Citations: 5     Fields:    Translation:Humans
    153. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant. 2008 Jun; 14(6):672-84. PMID: 18489993; PMCID: PMC4230823.
      Citations: 69     Fields:    Translation:HumansCellsCTClinical Trials
    154. Valdez BC, Murray D, Ramdas L, de Lima M, Jones R, Kornblau S, Betancourt D, Li Y, Champlin RE, Andersson BS. Altered gene expression in busulfan-resistant human myeloid leukemia. Leuk Res. 2008 Nov; 32(11):1684-97. PMID: 18339423; PMCID: PMC2633244.
      Citations: 26     Fields:    Translation:HumansCells
    155. Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D, Savoie ML, Bahlis NJ, Brown C, Storek J, Andersson BS, Russell JA. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant. 2008 Feb; 14(2):220-8. PMID: 18215782.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    156. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008 Feb; 93(2):257-64. PMID: 18223284; PMCID: PMC4238917.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    157. de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, Hosing C, Khouri I, Jones R, Champlin R, Karandish S, Sadeghi T, Peled T, Grynspan F, Daniely Y, Nagler A, Shpall EJ. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant. 2008 May; 41(9):771-8. PMID: 18209724; PMCID: PMC4086223.
      Citations: 88     Fields:    Translation:HumansCellsCTClinical Trials
    158. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008 Feb; 22(2):258-64. PMID: 17989720.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    159. Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F, Shpall E, Kebriaei P, Champlin R, de Lima M. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer. 2007 Jul 15; 110(2):340-4. PMID: 17559140.
      Citations: 16     Fields:    Translation:Humans
    160. Bao F, Polk P, Nordberg ML, Veillon DM, Sun A, Deininger M, Murray D, Andersson BS, Munker R. Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov; 31(11):1511-20. PMID: 17403535.
      Citations: 5     Fields:    Translation:HumansCells
    161. Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C, Ghosh S, Neumann J, Hsu Y, De Jesus J, Qazilbash MH, Champlin RE, Couriel DR. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood. 2007 Apr 01; 109(7):2751-8. PMID: 17138825.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    162. Madden T, de Lima M, Thapar N, Nguyen J, Roberson S, Couriel D, Pierre B, Shpall EJ, Jones RB, Champlin RE, Andersson BS. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant. 2007 Jan; 13(1):56-64. PMID: 17222753.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    163. Nilsson F, Andersson B, Bergh CH, Jeppsson A, Westerlind A. Long-term outcome in heart failure patients evaluated for heart transplantation but considered too well. Transplant Proc. 2006 Oct; 38(8):2689-90. PMID: 17098040.
      Citations:    Fields:    Translation:Humans
    164. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, de Lima M. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006 Aug 15; 108(4):1421-3. PMID: 16601247.
      Citations: 29     Fields:    Translation:Humans
    165. Yang H, Eaves C, de Lima M, Lee MS, Champlin RE, McMannis JD, Robinson SN, Niu T, Decker WK, Xing D, Ng J, Li S, Yao X, Eaves AC, Jones R, Andersson BS, Shpall EJ. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts. Bone Marrow Transplant. 2006 Mar; 37(6):575-82. PMID: 16435011.
      Citations: 4     Fields:    Translation:HumansCells
    166. Janson V, Behnam-Motlagh P, Henriksson R, Grankvist K, Andersson B. Induction of apoptosis by intracellular potassium ion depletion: using the fluorescent dye PBFI in a 96-well plate method in cultured lung cancer cells. Toxicol In Vitro. 2006 Sep; 20(6):986-94. PMID: 16483738.
      Citations: 13     Fields:    Translation:HumansCells
    167. Alder J, Andersson B, Karlsson-Parra A, Wallgren AC, B?cker AE. The direct pathway of human T-Cell allorecognition is not tolerized by stimulation with allogeneic peripheral blood mononuclear cells irradiated with high-dose ultraviolet B. Scand J Immunol. 2006 Feb; 63(2):90-6. PMID: 16476007.
      Citations:    Fields:    Translation:HumansCells
    168. Nordmark B, Blomqvist P, Andersson B, Nordh-Grate K, Svensson H, Klareskog L, H?gerstr?m M, R?nnqvist R. A two-year follow-up of work capacity in early rheumatoid arthritis: a study of multidisciplinary team care with emphasis on vocational support. Scand J Rheumatol. 2006 Jan-Feb; 35(1):7-14. PMID: 16467034.
      Citations: 1     Fields:    Translation:Humans
    169. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, Smith V, Khouri I, Giralt S, de Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato M. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006 Apr 15; 107(8):3074-80. PMID: 16368882.
      Citations: 60     Fields:    Translation:Humans
    170. Aurelius E, Hjalmarsson A, Sabri F, Forsgren M, Andersson B, Linde A, Studahl M, Hagberg L, Rosengren L, Sk?ldenberg B, Stranneg?rd O. Incidence and pathogenesis of clinical relapse after herpes simplex encephalitis in adults. J Neurol. 2006 Feb; 253(2):163-70. PMID: 16222428.
      Citations: 50     Fields:    Translation:Humans
    171. Couriel DR, Saliba R, Hsu Y, Ghosh S, Ippoliti C, Hicks K, Donato M, Giralt S, Khouri IF, Hosing C, de Lima MJ, Andersson B, Neumann J, Champlin R, Escal?n MP. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol. 2005 Aug; 130(3):409-17. PMID: 16042691.
      Citations: 52     Fields:    Translation:HumansCTClinical Trials
    172. Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S, Andersson B, Champlin RE, De Lima M. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant. 2005 Jul; 36(2):157-62. PMID: 15937511.
      Citations: 15     Fields:    Translation:Humans
    173. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 2005 May; 35(10):943-51. PMID: 15806128.
      Citations: 30     Fields:    Translation:Humans
    174. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005 Feb; 11(2):108-14. PMID: 15682071.
      Citations: 35     Fields:    Translation:Humans
    175. Tran H, Petropoulos D, Worth L, Mullen CA, Madden T, Andersson B, Choroszy M, Nguyen J, Webb SK, Chan KW. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2004 Nov; 10(11):805-12. PMID: 15505611.
      Citations: 11     Fields:    Translation:Humans
    176. Anderlini P, Acholonu SA, Okoroji GJ, Andersson BS, Couriel DR, De Lima MJ, Donato ML, Khouri IF, Giralt SA, Ueno NT, Champlin RE. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant. 2004 Sep; 34(6):511-4. PMID: 15273710.
      Citations: 10     Fields:    Translation:Humans
    177. Andersson R, Andersson B, Haraldsen P, Drewsen G, Eckerwall G. Incidence, management and recurrence rate of acute pancreatitis. Scand J Gastroenterol. 2004 Sep; 39(9):891-4. PMID: 15513389.
      Citations: 32     Fields:    Translation:Humans
    178. Thall PF, Champlin RE, Andersson BS. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant. 2004 Jun; 33(12):1191-9. PMID: 15122310.
      Citations: 9     Fields:    Translation:Humans
    179. Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S, Rodriguez M, Romaguera J, Hagemeister F, Ha C, Cox J, Cabanillas F, Andersson BS, Champlin RE. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 May; 33(10):1015-23. PMID: 15048145.
      Citations: 13     Fields:    Translation:Humans
    180. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004 Aug 01; 104(3):865-72. PMID: 15090449.
      Citations: 95     Fields:    Translation:Humans
    181. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004 Aug 01; 104(3):857-64. PMID: 15073038.
      Citations: 143     Fields:    Translation:Humans
    182. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004 Aug 01; 104(3):649-54. PMID: 15069017.
      Citations: 58     Fields:    Translation:Humans
    183. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewski J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin R. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant. 2004 Mar; 10(3):178-85. PMID: 14993883.
      Citations: 48     Fields:    Translation:Humans
    184. Khouri IF, Lee MS, Saliba RM, Andersson B, Anderlini P, Couriel D, Hosing C, Giralt S, Korbling M, McMannis J, Keating MJ, Champlin RE. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol. 2004 Jan; 32(1):28-35. PMID: 14725898.
      Citations: 32     Fields:    Translation:Humans
    185. Andersson BS, Kashyap A, Couriel D, Madden T, de Lima M, Thall PF, Fernandez H, Vaughan WP, Jones R, Wingard JR, Blume KG, Champlin RE. Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. Biol Blood Marrow Transplant. 2003 Nov; 9(11):722-4. PMID: 14682302.
      Citations: 2     Fields:    Translation:Humans
    186. Andersson B, Darius M, Delius W, Goss F, Osterziel KJ, Sigmund M, Trenkwalder SP, Wahlqvist I, Waagstein F, Str?mblad O, B?hm M. Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2003 Oct; 5(5):679-91. PMID: 14607208.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    187. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima M. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003 Oct 15; 102(8):3052-9. PMID: 12842990.
      Citations: 42     Fields:    Translation:HumansCells
    188. Hosing C, Saliba RM, McLaughlin P, Andersson B, Rodriguez MA, Fayad L, Cabanillas F, Champlin RE, Khouri IF. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol. 2003 May; 14(5):737-44. PMID: 12702528.
      Citations: 20     Fields:    Translation:Humans
    189. de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003 Mar 01; 97(5):1242-7. PMID: 12599231.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    190. Wang XR, Andersson B, Yin TM, Lerceteau-K?hler E. Nearly complete genetic maps of Pinus sylvestris L. (Scots pine) constructed by AFLP marker analysis in a full-sib family. Theor Appl Genet. 2003 Apr; 106(6):1075-83. PMID: 12671756.
      Citations: 10     Fields:    Translation:Animals
    191. Januszkiewicz A, Andersson B, McNurlan MA, Garlick PJ, Andersson J, Wernerman J, Lor? K, Ess?n P, Ringd?n O. Response of in vivo protein synthesis in T lymphocytes and leucocytes to an endotoxin challenge in healthy volunteers. Clin Exp Immunol. 2002 Nov; 130(2):263-70. PMID: 12390314; PMCID: PMC1906514.
      Citations: 4     Fields:    Translation:HumansCells
    192. Andersson BS. Essential thrombocythemia: diagnosis and treatment, with special emphasis on the use of anagrelide. Hematology. 2002 Jun; 7(3):173-7. PMID: 12243981.
      Citations:    Fields:    Translation:HumansCells
    193. Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, Martin T, Ueno NT, Champlin RE, Khouri IF, K?rbling M. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol. 2002 Mar; 13(3):450-9. PMID: 11996478.
      Citations: 18     Fields:    Translation:Humans
    194. Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, Jones RB, Tarantolo S, Hu WW, Blume KG, Forman SJ, Champlin RE. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant. 2002; 8(3):145-54. PMID: 11939604.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    195. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, Stewart D, Ruether JD, Morris D, Glick S, Gyonyor E, Andersson BS. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002; 8(9):468-76. PMID: 12374451.
      Citations: 85     Fields:    Translation:HumansCTClinical Trials
    196. Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J, Champlin RE. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002; 8(9):477-85. PMID: 12374452.
      Citations: 63     Fields:    Translation:HumansCTClinical Trials
    197. Murray D, Vallee-Lucic L, Rosenberg E, Andersson B. Sensitivity of nucleotide excision repair-deficient human cells to ionizing radiation and cyclophosphamide. Anticancer Res. 2002 Jan-Feb; 22(1A):21-6. PMID: 12017289.
      Citations: 5     Fields:    Translation:HumansCells
    198. Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, Blume K, Niland J, Palmer JM, Vaughan W, Fernandez H, Champlin R, Forman S, Andersson BS. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002; 8(9):493-500. PMID: 12374454.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    199. Gajewski JL, Rondon G, Donato ML, Anderlini P, Korbling M, Ippoliti C, Benyunes M, Miller LL, LaTemple D, Jones D, Ashby M, Hellmann S, Durett A, Lauppe J, Geisler D, Khouri IF, Giralt SA, Andersson B, Ueno NT, Champlin R. Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization. Biol Blood Marrow Transplant. 2002; 8(10):550-6. PMID: 12434950.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    200. Andersson BS, Murray D. Model studies of cyclophosphamide resistance in human myeloid leukemia. Cancer Treat Res. 2002; 112:211-35. PMID: 12487104.
      Citations: 1     Fields:    Translation:HumansCells
    201. Andersson B, Odman P. Procera AllCeram crowns followed for 5 to 10.5 years: a prospective clinical study. Int J Prosthodont. 2001 Nov-Dec; 14(6):504-9. PMID: 12066695.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    202. Gopal R, Ha CS, Tucker SL, Khouri IF, Giralt SA, Gajewski JL, Andersson BS, Cox JD, Champlin RE. Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity. Cancer. 2001 Oct 01; 92(7):1949-58. PMID: 11745270.
      Citations: 19     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    203. Rodriguez J, Munsell M, Yazji S, Hagemeister FB, Younes A, Andersson B, Giralt S, Gajewski J, de Lima M, Couriel D, Romaguera J, Cabanillas FF, Champlin RE, Khouri IF. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol. 2001 Sep 01; 19(17):3766-70. PMID: 11533100.
      Citations: 25     Fields:    Translation:Humans
    204. Andersson B, Taylor A, Lang BR, Scheller H, Sch?rer P, Sorensen JA, Tarnow D. Alumina ceramic implant abutments used for single-tooth replacement: a prospective 1- to 3-year multicenter study. Int J Prosthodont. 2001 Sep-Oct; 14(5):432-8. PMID: 12066638.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    205. Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol. 2001 Aug; 67(4):227-33. PMID: 11443634.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    206. Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno N, deVos D, Champlin R, Giralt S. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant. 2001 Jun; 27(12):1221-5. PMID: 11548839.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    207. Shimoni A, Smith TL, Aleman A, Weber D, Dimopoulos M, Anderlini P, Andersson B, Claxton D, Ueno NT, Khouri I, Donato M, Korbling M, Alexanian R, Champlin R, Giralt S. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant. 2001 Apr; 27(8):821-8. PMID: 11477439.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    208. Kontoyiannis DP, Andersson BS, Lewis RE, Raad II. Progressive disseminated aspergillosis in a bone marrow transplant recipient: response with a high-dose lipid formulation of amphotericin B. Clin Infect Dis. 2001 Mar 01; 32(5):E94-6. PMID: 11229866.
      Citations: 8     Fields:    Translation:HumansAnimals
    209. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001 Feb 01; 97(3):631-7. PMID: 11157478.
      Citations: 106     Fields:    Translation:HumansCTClinical Trials
    210. van Besien K, Rodriguez A, Tomany S, Younes A, Donato M, Sarris A, Giralt S, Mehra R, Andersson B, Gajewski J, Champlin R, Cabanillas F. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplant. 2001 Feb; 27(4):397-404. PMID: 11313669.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    211. Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Manning J, Romaguera J, Sarris A, Hagemeister F, Mclaughlin P, Cabanillas F, Champlin RE, K?rbling MJ. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant. 2000 Sep; 26(6):615-20. PMID: 11041566.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    212. de Lima M, van Besien K, Gajewski J, Khouri I, Andersson B, Korbling M, Champlin R, Giralt S. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. Bone Marrow Transplant. 2000 Aug; 26(3):333-8. PMID: 10967575.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    213. Andersson BS, Gajewski J, Donato M, Giralt S, Gian V, Wingard J, Tarantolo S, Fernandez H, Hu WW, Blume K, Kashyap A, Forman SJ, Champlin RE. Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplant. 2000 May; 25 Suppl 2:S35-8. PMID: 10933185.
      Citations: 7     Fields:    Translation:Humans
    214. O'Brien KP, Kost-Alimova M, Kedra D, Bruder CE, Andersson B, Roe BA, Hu P, Imreh S, Blennow E, Dumanski JP, Tapia-P?ez I, Sahl?n S. Fine mapping of the constitutional translocation t(11;22)(q23;q11). Hum Genet. 2000 May; 106(5):506-16. PMID: 10914680.
      Citations: 9     Fields:    Translation:HumansCells
    215. Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000 Feb 02; 92(3):225-33. PMID: 10655439.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    216. Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS, Champlin RE, Vaughan WP. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant. 2000; 6(5A):548-54. PMID: 11071260.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    217. Przepiorka D, Saliba R, Cleary K, Fischer H, Tonai R, Fritsche H, Khouri IF, Folloder J, Ueno NT, Mehra R, Ippoliti C, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Anderlini P, Andersson BS, Champlin R. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biol Blood Marrow Transplant. 2000; 6(2A):190-7. PMID: 10816027.
      Citations: 1     Fields:    Translation:Humans
    218. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, Lu JG, Gajewski J, Durett A, Cleary K, Champlin R, Andersson BS, Light S. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 2000 Jan 01; 95(1):83-9. PMID: 10607689.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    219. Blange I, Andersson B, Sylv?n C. Angiotensin-II type 1 receptor gene polymorphism and long-term survival in patients with idiopathic congestive heart failure. Eur J Heart Fail. 1999 Dec; 1(4):363-9. PMID: 10937949.
      Citations: 16     Fields:    Translation:Humans
    220. Przepiorka D, Khouri I, Ippoliti C, Ueno NT, Mehra R, Giralt S, Gajewski J, Fischer H, Donato M, Cleary K, Claxton D, Chan KW, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R, K?rbling M. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant. 1999 Oct; 24(7):763-8. PMID: 10516680.
      Citations: 21     Fields:    Translation:Humans
    221. Donato ML, Champlin RE, Van Besien KW, Korbling M, Cabanillas F, Anderlini P, Gajewski JG, Lauppe J, Durett A, Andersson B, Giralt S, Khouri I, Hagemeister F, Romaguera JE, Sarris A, McLaughlin P, Younes A, Ippoliti C, Blamble DA, Hester J, Gee A, Rodriguez MA. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1999 Oct; 35(3-4):317-24. PMID: 10706456.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    222. Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R, Huh YO, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R, K?rbling M. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999 Aug 15; 94(4):1465-70. PMID: 10438735.
      Citations: 43     Fields:    Translation:Humans
    223. Gamcsik MP, Dolan ME, Andersson BS, Murray D. Mechanisms of resistance to the toxicity of cyclophosphamide. Curr Pharm Des. 1999 Aug; 5(8):587-605. PMID: 10469893.
      Citations: 13     Fields:    Translation:HumansAnimals
    224. Andersson BS, Eksborg S, Vidal RF, Sundberg M, Carlberg M. Anthraquinone-induced cell injury: acute toxicity of carminomycin, epirubicin, idarubicin and mitoxantrone in isolated cardiomyocytes. Toxicology. 1999 Jul 01; 135(1):11-20. PMID: 10454220.
      Citations: 3     Fields:    Translation:Animals
    225. Rodriguez J, Rodriguez MA, Fayad L, McLaughlin P, Swan F, Sarris A, Romaguera J, Andersson B, Cabanillas F, Hagemeister FB. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood. 1999 Jun 01; 93(11):3632-6. PMID: 10339468.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    226. Przepiorka D, Khouri I, Thall P, Mehra R, Lee MS, Ippoliti C, Giralt S, Gajewski J, van Besien K, Andersson B, Deisseroth AB, Champlin R, K?rbling M. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant. 1999 May; 23(10):977-81. PMID: 10373061.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    227. Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R, K?rbling M. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May; 10(5):527-32. PMID: 10416001.
      Citations: 15     Fields:    Translation:Humans
    228. Lomsky M, Waagstein F, Andersson B, Str?mblad SO. Heart rate dependency of cardiac performance in heart failure patients treated with metoprolol. Eur Heart J. 1999 Apr; 20(8):575-83. PMID: 10337542.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    229. Andersson B, Di Lenarda A, Rundqvist B, Sinagra G, Hjalmarson A, Waagstein F, Wennerblom B, Tygesen H. Potential risk of beta-blockade withdrawal in congestive heart failure due to abrupt autonomic changes. Int J Cardiol. 1999 Feb 28; 68(2):171-7. PMID: 10189005.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    230. Draptchinskaia N, Gustavsson P, Andersson B, Pettersson M, Willig TN, Dianzani I, Ball S, Tchernia G, Klar J, Matsson H, Tentler D, Mohandas N, Carlsson B, Dahl N. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet. 1999 Feb; 21(2):169-75. PMID: 9988267.
      Citations: 326     Fields:    Translation:HumansCells
    231. Andersson B, Waagstein F, Bergh CH, Lindel?w B. High and low pulmonary vascular resistance in heart transplant candidates. A 5-year follow-up after heart transplantation shows continuous reduction in resistance and no difference in complication rate. Eur Heart J. 1999 Jan; 20(2):148-56. PMID: 10099912.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    232. Pauksen K, Linde A, Andersson B, Lenkei R, Oberg G, Ljungman P, Sj?lin J. Subsets of T-cells and in vitro cytokine production after measles and varicellae-zoster virus antigen stimulation in allogeneic BMT patients. Scand J Infect Dis. 1999; 31(1):43-9. PMID: 10381217.
      Citations:    Fields:    Translation:HumansCells
    233. Gajewski JL, Nimer S, Saliba RM, Thomas M, Przepiorka D, Giralt S, von Besien K, Mehra R, Andersson B, Chan KW, Ippoliti C, Warkinten D, Feigs S, Territo M, Schiller G, Lebkowski J, Moseley AM, Lloyd K, von Hoeff M, Okarma T, Champlin R. Long-term outcome of a phase II study of BM transplants, partially depleted ex-vivo of CD5-positive and CD8-positive T-lymphocytes in unrelated and related donor 1 antigen mismatched recipients. Cytotherapy. 1999; 1(5):401-7. PMID: 20426540.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    234. Munker R, Zhao S, Jiang S, Snell V, Andreeff M, Andersson BS. Further characterization of cyclophosphamide resistance: expression of CD95 and of bcl-2 in a CML cell line. Leuk Res. 1998 Nov; 22(11):1073-7. PMID: 9783811.
      Citations: 2     Fields:    Translation:HumansCells
    235. Price KJ, Thall PF, Kish SK, Shannon VR, Andersson BS. Prognostic indicators for blood and marrow transplant patients admitted to an intensive care unit. Am J Respir Crit Care Med. 1998 Sep; 158(3):876-84. PMID: 9731020.
      Citations: 27     Fields:    Translation:Humans
    236. Khouri IF, Keating M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R, K?rbling M. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998 Aug; 16(8):2817-24. PMID: 9704734.
      Citations: 114     Fields:    Translation:Humans
    237. Andersson B, Aslund L, Tammi M, Tran AN, Hoheisel JD, Pettersson U. Complete sequence of a 93.4-kb contig from chromosome 3 of Trypanosoma cruzi containing a strand-switch region. Genome Res. 1998 Aug; 8(8):809-16. PMID: 9724326; PMCID: PMC310758.
      Citations: 13     Fields:    Translation:AnimalsCells
    238. Ueno NT, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi GN, Champlin RE, Rond?n G, K?rbling M. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998 Mar; 16(3):986-93. PMID: 9508181.
      Citations: 21     Fields:    Translation:Humans
    239. Popat U, Przepiork D, Champlin R, Pugh W, Amin K, Mehra R, Rodriguez J, Giralt S, Romaguera J, Rodriguez A, Preti A, Andersson B, Khouri I, Claxton D, de Lima M, Donato M, Anderlini P, Gajewski J, Cabanillas F, van Besien K. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol. 1998 Jan; 16(1):63-9. PMID: 9440724.
      Citations: 11     Fields:    Translation:Humans
    240. Chow DS, Bhagwatwar HP, Phadungpojna S, Andersson BS. Stability-indicating high-performance liquid chromatographic assay of busulfan in aqueous and plasma samples. J Chromatogr B Biomed Sci Appl. 1997 Dec 19; 704(1-2):277-88. PMID: 9518161.
      Citations: 1     Fields:    Translation:Animals
    241. Vriesendorp HM, Quadri SM, Andersson BS, Wyllie CT, Dicke KA. Recurrence of Hodgkin's disease after indium-111 and yttrium-90 labeled antiferritin administration. Cancer. 1997 Dec 15; 80(12 Suppl):2721-7. PMID: 9406730.
      Citations:    Fields:    Translation:Humans
    242. Dignani MC, Anaissie EJ, Hester JP, O'Brien S, Vartivarian SE, Rex JH, Kantarjian H, Jendiroba DB, Lichtiger B, Andersson BS, Freireich EJ. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia. 1997 Oct; 11(10):1621-30. PMID: 9324280.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    243. Ippoliti C, Morgan A, Warkentin D, van Besien K, Mehra R, Khouri I, Giralt S, Gajewski J, Champlin R, Andersson B, Przepiorka D. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplant. 1997 Sep; 20(6):491-5. PMID: 9313883.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    244. van Besien K, Thall P, Korbling M, Pugh WC, Khouri I, Mehra R, Giralt S, Anderlini P, Amin K, Mirza N, Seong D, Gajewski J, Hester J, Andersson B, Cabanillas F, Champlin R, Przepiorka D. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant. 1997 Aug; 3(3):150-6. PMID: 9310192.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    245. Pauksen K, Linde A, Alm G, Andersson B, Ljungman P, Sj?lin J, L?nnerholm G. Th1 and Th2 cytokine responses after measles antigen stimulation in vitro in bone marrow transplant patients: response to measles vaccination. Bone Marrow Transplant. 1997 Aug; 20(4):317-23. PMID: 9285547.
      Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
    246. Giralt S, Estey E, Albitar M, van Besien K, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Keating M, Kantarjian H, Champlin R, Rond?n G, K?rbling M. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15; 89(12):4531-6. PMID: 9192777.
      Citations: 159     Fields:    Translation:HumansCTClinical Trials
    247. Gajewski J, Gjertson D, Cecka M, Tonai R, Przepiorka D, Hunt L, Giralt S, Chan KW, Feig S, Territo M, Andersson B, van Besien K, Khouri I, Fischer H, Babbitt L, Ippolitti C, Schiller G, Lill M, Warkentin D, Neumann J, Petz L, Terasaki P, Champlin R. The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 1997 Jun; 3(2):76-82. PMID: 9267667.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    248. Khouri IF, Przepiorka D, van Besien K, O'Brien S, Palmer JL, Lerner S, Mehra RC, Vriesendorp HM, Andersson BS, Giralt S, Keating MJ, Champlin RE, K?rbling M. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol. 1997 May; 97(2):466-73. PMID: 9163617.
      Citations: 9     Fields:    Translation:Humans
    249. van Besien KW, de Lima M, Giralt SA, Moore DF, Khouri IF, Mehra R, Andersson BS, Dyer C, Cleary K, Przepiorka D, Gajewski JL, Champlin RE, Rond?n G. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant. 1997 May; 19(10):977-82. PMID: 9169641.
      Citations: 29     Fields:    Translation:Humans
    250. Yu W, Andersson B, Worley KC, Muzny DM, Ding Y, Liu W, Ricafrente JY, Wentland MA, Lennon G, Gibbs RA. Large-scale concatenation cDNA sequencing. Genome Res. 1997 Apr; 7(4):353-8. PMID: 9110174; PMCID: PMC139146.
      Citations: 17     Fields:    Translation:HumansCells
    251. Przepiorka D, Anderlini P, Ippoliti C, Khouri I, Fietz T, Thall P, Mehra R, Giralt S, Gajewski J, Deisseroth AB, Cleary K, Champlin R, van Besien K, Andersson B, K?rbling M. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant. 1997 Mar; 19(5):455-60. PMID: 9052911.
      Citations: 3     Fields:    Translation:Humans
    252. Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K, Gajewski J, Andersson B, Khouri I, Przepiorka D, von Wolff B, Delasalle K, Korbling M, Seong D, Alexanian R, Champlin R. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol. 1997 Feb; 15(2):667-73. PMID: 9053492.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    253. Andersson B, Lu J, Shen Y, Wentland MA, Gibbs RA. Simultaneous shotgun sequencing of multiple cDNA clones. DNA Seq. 1997; 7(2):63-70. PMID: 9063643.
      Citations: 5     Fields:    Translation:Animals
    254. Verschraegen CF, van Besien KW, Dignani C, Hester JP, Andersson BS, Anaissie E. Invasive Aspergillus sinusitis during bone marrow transplantation. Scand J Infect Dis. 1997; 29(4):436-8. PMID: 9360268.
      Citations: 3     Fields:    Translation:HumansCells
    255. de Lima M, van Besien KW, Giralt SA, Khouri IF, Mehra R, Andersson BS, Przepiorka D, Gajewski JL, Korbling M, Champlin RE. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997 Jan; 19(2):121-7. PMID: 9116608.
      Citations: 9     Fields:    Translation:Humans
    256. Engervall P, Andersson B, Kalin M, Granstr?m M, Bj?rkholm M. Endotoxemia in febrile patients with hematological malignancies. Relationship of type of bacteremia, clinical findings and serum cytokine pattern. Infection. 1997 Jan-Feb; 25(1):2-7. PMID: 9039529.
      Citations: 5     Fields:    Translation:Humans
    257. Przepiorka D, Ippoliti C, Khouri I, Anderlini P, Mehra R, Giralt S, Gajewski J, Fritsche H, Deisseroth AB, Cleary K, Champlin R, van Besien K, Andersson B, Korbling M. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation. 1996 Dec 27; 62(12):1806-10. PMID: 8990368.
      Citations: 1     Fields:    Translation:Humans
    258. Przepiorka D, Ippoliti C, Khouri I, Woo M, Mehra R, Le Bherz D, Giralt S, Gajewski J, Fischer H, Fritsche H, Deisseroth AB, Cleary K, Champlin R, Besien K, Andersson B, Maher R, Fitzsimmons W. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood. 1996 Dec 01; 88(11):4383-9. PMID: 8943876.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    259. Anderlini P, Durett A, Maadani F, Bojko P, Seong D, Giralt S, Khouri I, Andersson B, Mehra R, vanBesien K, Mirza N, Przepiorka D, Champlin R, K?rbling M. Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone Marrow Transplant. 1996 Dec; 18(6):1073-9. PMID: 8971375.
      Citations: 1     Fields:    Translation:HumansCells
    260. Vidal RF, Eksborg S, Sundberg M, Carlberg M, Elfsson B, Andersson BS. Doxorubicin- and daunorubicin-induced energy deprivation and nucleotide degradation in isolated cardiomyocytes. Toxicology. 1996 Nov 15; 114(1):1-10. PMID: 8931755.
      Citations: 3     Fields:    Translation:AnimalsCells
    261. Chan KW, Anderlini P, Seong D, Durett A, Langlinais A, Przepiorka D, Gajewski J, Miller P, Sundberg J, Alilaen P, Bojko P, Mirza N, Claxton D, van Besien K, Khouri I, Andersson B, Mehra R, Champlin R, K?rbling M. Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors. Bone Marrow Transplant. 1996 Nov; 18(5):885-90. PMID: 8932841.
      Citations: 1     Fields:    Translation:HumansCells
    262. van Besien K, Przepiorka D, Mehra R, Giralt S, Khouri I, Gajewski J, Andersson B, Champlin R. Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. J Clin Oncol. 1996 Nov; 14(11):3036-42. PMID: 8918502.
      Citations: 6     Fields:    Translation:Humans
    263. Giralt S, Huh Y, Khouri I, Andersson B, Andreeff M, Champlin R, Rond?n G. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant. 1996 Sep; 18(3):669-72. PMID: 8879640.
      Citations: 17     Fields:    Translation:Humans
    264. Vriesendorp HM, Quadri SM, Andersson BS, Dicke KA. Hematologic side effects of radiolabeled immunoglobulin therapy. Exp Hematol. 1996 Aug; 24(10):1183-90. PMID: 8765492.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    265. Andersson B, Sylv?n C. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol. 1996 Jul; 28(1):162-7. PMID: 8752809.
      Citations: 29     Fields:    Translation:Humans
    266. Andersson B, Lu J, Edwards KE, Muzny DM, Gibbs RA. Method for 96-well M13 DNA template preparations for large-scale sequencing. Biotechniques. 1996 Jun; 20(6):1022-7. PMID: 8780873.
      Citations: 5     Fields:    Translation:Cells
    267. Andersson B, Wentland MA, Ricafrente JY, Liu W, Gibbs RA. A "double adaptor" method for improved shotgun library construction. Anal Biochem. 1996 Apr 05; 236(1):107-13. PMID: 8619474.
      Citations: 20     Fields:    Translation:HumansCells
    268. Roobol-Boza M, Andersson B. Isolation of hydrophobic membrane proteins by perfusion chromatography--purification of photosystem II reaction centers from spinach chloroplasts. Anal Biochem. 1996 Mar 15; 235(2):127-33. PMID: 8833320.
      Citations: 3     Fields:    Translation:AnimalsCells
    269. Kjellman B, Gidlund M, Andersson B, Jindal S, Kiessling R, Frosteg?rd J. Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein. Atherosclerosis. 1996 Mar; 121(1):93-103. PMID: 8678928.
      Citations: 16     Fields:    Translation:HumansCells
    270. van Besien KW, Mehra RC, Giralt SA, Kantarjian HM, Pugh WC, Khouri IF, Moon Y, Williams P, Andersson BS, Przepiorka D, McCarthy PL, Gajewski JL, Deisseroth AB, Cabanillas FF, Champlin R. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med. 1996 Mar; 100(3):299-307. PMID: 8629675.
      Citations: 12     Fields:    Translation:Humans
    271. Andersson BS, Vidal RF, Sundberg M, Rajs J, S?tonyi P. Hydroperoxide-induced nucleotide degradation and adenosine formation in isolated rat cardiomyocytes. Toxicology. 1996 Jan 08; 106(1-3):39-48. PMID: 8571400.
      Citations: 9     Fields:    Translation:AnimalsCells
    272. Andersson BS, Sadeghi T, Siciliano MJ, Legerski R, Murray D. Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother Pharmacol. 1996; 38(5):406-16. PMID: 8765433.
      Citations: 33     Fields:    Translation:AnimalsCells
    273. Bhagwatwar HP, Phadungpojna S, Chow DS, Andersson BS. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol. 1996; 37(5):401-8. PMID: 8599861.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    274. Andersson BS, Collins VP, Kurzrock R, Larkin DW, Childs C, Ost A, Cork A, Trujillo JM, Freireich EJ, Siciliano MJ, et al. KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. Leukemia. 1995 Dec; 9(12):2100-8. PMID: 8609723.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    275. Ippoliti C, Przepiorka D, Mehra R, Neumann J, Wood J, Claxton D, Gajewski J, Khouri I, van Besien K, Andersson B, et al. Intravesicular carboprost for the treatment of hemorrhagic cystitis after marrow transplantation. Urology. 1995 Dec; 46(6):811-5. PMID: 7502421.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    276. Andersson BS, Hahn RG, Zhang W. Effect of irrigating fluids and prostate tissue extracts on isolated cardiomyocytes. Urology. 1995 Dec; 46(6):821-4. PMID: 7502423.
      Citations: 3     Fields:    Translation:AnimalsCells
    277. Engervall P, Andersson B, Bj?rkholm M. Clinical significance of serum cytokine patterns during start of fever in patients with neutropenia. Br J Haematol. 1995 Dec; 91(4):838-45. PMID: 8547127.
      Citations: 9     Fields:    Translation:Humans
    278. Andersson B, Waagstein F, Bergh CH, Lindel?w B. Prognosis of alternative therapies in patients with heart failure not accepted for heart transplantation. J Heart Lung Transplant. 1995 Nov-Dec; 14(6 Pt 1):1204-11. PMID: 8719468.
      Citations: 2     Fields:    Translation:Humans
    279. Andersson B, Andersson K, Kussak A. Immunoaffinity column clean-up for the high-performance liquid chromatographic determination of aflatoxins B1, B2, G1, G2, M1 and Q1 in urine. J Chromatogr B Biomed Appl. 1995 Oct 20; 672(2):253-9. PMID: 8581131.
      Citations: 3     Fields:    Translation:Humans
    280. Andersson B, Eriksson S, Rundgren M. Angiotensin and the brain. Acta Physiol Scand. 1995 Oct; 155(2):117-25. PMID: 8669284.
      Citations: 3     Fields:    Translation:HumansAnimals
    281. Sen S, Zhou H, Andersson BS, Cork A, Freireich EJ, Stass SA. p53 gene mutations with chromosome 17 abnormalities in chronic myelogenous leukemia blast crisis patients persist in long-term cell lines but may be acquired in acute myeloid leukemia cells in vitro. Cancer Genet Cytogenet. 1995 Jul 01; 82(1):35-40. PMID: 7627932.
      Citations: 1     Fields:    Translation:HumansCells
    282. Talpaz M, Kantarjian H, Liang J, Calvert L, Hamer J, Tibbits P, Durett A, Claxton D, Giralt S, Khouri I, et al. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood. 1995 Jun 01; 85(11):3257-63. PMID: 7756658.
      Citations: 3     Fields:    Translation:HumansCells
    283. Giralt S, O'Brien S, Talpaz M, Van Besien K, Chan KW, Andersson B, Mehra R, Khouri I, Estey E, Rond?n G, et al. Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation. Cytokines Mol Ther. 1995 Jun; 1(2):115-22. PMID: 9384668.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    284. van Besien KW, Khouri IF, Giralt SA, McCarthy P, Mehra R, Andersson BS, Przepiorka D, Gajewski JL, Bellare N, Nath R, et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol. 1995 May; 13(5):1096-102. PMID: 7738615.
      Citations: 6     Fields:    Translation:Humans
    285. Przepiorka D, Nath R, Ippoliti C, Mehra R, Hagemeister F, Diener K, Dimopoulos M, Giralt S, Khouri I, Samuels B, et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymphoma. 1995 May; 17(5-6):427-33. PMID: 7549833.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    286. van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I, et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant. 1995 Apr; 15(4):549-55. PMID: 7655380.
      Citations: 6     Fields:    Translation:Humans
    287. Engervall P, Andersson B, Granstr?m M, Bj?rkholm M. Monitoring of endotoxin, interleukin-6 and C-reactive protein serum concentrations in neutropenic patients with fever. Eur J Haematol. 1995 Apr; 54(4):226-34. PMID: 7789467.
      Citations: 7     Fields:    Translation:Humans
    288. Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, Andersson B, Kleine HD, Seong D, Deisseroth AB, K?rbling M, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995 Mar 15; 85(6):1659-65. PMID: 7888684.
      Citations: 30     Fields:    Translation:HumansCells
    289. Waller LA, Turnbull BW, Gustafsson G, Hjalmars U, Andersson B. Detection and assessment of clusters of disease: an application to nuclear power plant facilities and childhood leukaemia in Sweden. Stat Med. 1995 Jan 15; 14(1):3-16. PMID: 7701156.
      Citations: 11     Fields:    Translation:HumansPHPublic Health
    290. Andersson B, Caidahl K, Waagstein F. Idiopathic dilated cardiomyopathy among Swedish patients with congestive heart failure. Eur Heart J. 1995 Jan; 16(1):53-60. PMID: 7737223.
      Citations: 6     Fields:    Translation:Humans
    291. Andersson BS, Mroue M, Britten RA, Farquhar D, Murray D. Mechanisms of cyclophosphamide resistance in a human myeloid leukemia cell line. Acta Oncol. 1995; 34(2):247-51. PMID: 7718264.
      Citations: 4     Fields:    Translation:HumansCells
    292. Andersson B, Lu F, Muzny DM, Warren ST, Gibbs RA. Complete sequence of a 38.4-kb human cosmid insert containing the polymorphic marker DXS455 from Xq28. DNA Seq. 1995; 5(4):219-23. PMID: 7626781.
      Citations: 2     Fields:    Translation:HumansCells
    293. Andersson BS, Mroue M, Britten RA, Murray D. The role of DNA damage in the resistance of human chronic myeloid leukemia cells to cyclophosphamide analogues. Cancer Res. 1994 Oct 15; 54(20):5394-400. PMID: 7923171.
      Citations: 5     Fields:    Translation:HumansCells
    294. Przepiorka D, Ippoliti C, Giralt S, van Beisen K, Mehra R, Deisseroth AB, Andersson B, Luna M, Cork A, Lee M, et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant. 1994 Sep; 14(3):449-53. PMID: 7994271.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    295. Giralt SA, LeMaistre CF, Vriesendorp HM, Andersson BS, Dimopoulos M, Gajewski J, Van Besien K, Mehra R, Przepiorka D, Khouri I, et al. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol. 1994 Sep; 12(9):1923-30. PMID: 8083714.
      Citations: 9     Fields:    Translation:Humans
    296. Kantarjian HM, Talpaz M, Andersson B, Khouri I, Giralt S, Rios MB, Champlin R, Hester J, Deisseroth AB. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia. Bone Marrow Transplant. 1994 Jul; 14(1):57-61. PMID: 7951120.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    297. Andersson B, Povinelli CM, Wentland MA, Shen Y, Muzny DM, Gibbs RA. Adaptor-based uracil DNA glycosylase cloning simplifies shotgun library construction for large-scale sequencing. Anal Biochem. 1994 May 01; 218(2):300-8. PMID: 8074284.
      Citations: 4     Fields:    Translation:HumansCells
    298. Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO, Andersson BS, van Besien KW, Mehra RC, Giralt SA, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol. 1994 Apr; 12(4):748-58. PMID: 8151318.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    299. Przepiorka D, Ippoliti C, Panina A, Goodrich J, Giralt S, van Besien K, Mehra R, Deisseroth AB, Andersson B, Luna M, et al. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplant. 1994 Apr; 13(4):461-4. PMID: 8019472.
      Citations: 1     Fields:    Translation:HumansCells
    300. Norling B, Mirzakhanian V, Nilsson F, Andersson B, Morr? DJ. Subfractional analysis of cyanobacterial membranes and isolation of plasma membranes by aqueous polymer two-phase partitioning. Anal Biochem. 1994 Apr; 218(1):103-11. PMID: 7519833.
      Citations: 2     Fields:    Translation:Cells
    301. Chryssanthou E, Andersson B, Petrini B, Tollemar J, L?fdahl S. Detection of Candida albicans DNA in serum by polymerase chain reaction. Scand J Infect Dis. 1994; 26(4):479-85. PMID: 7984982.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    302. Andersson B, Glim?ker M, Olc?n P. Interferon-gamma in cerebrospinal fluid from patients with viral and bacterial meningitis. Scand J Infect Dis. 1994; 26(2):141-7. PMID: 8036469.
      Citations: 17     Fields:    Translation:Humans
    303. Use of retroviral markers to identify efficacy of purging and origin of relapse following autologous bone marrow and peripheral blood cell transplantation in indolent B cell neoplasms (follicular non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL) patients). Hum Gene Ther. 1993 Dec; 4(6):821-34. PMID: 8186294.
      Citations:    Fields:    Translation:HumansCells
    304. Anaissie EJ, Kontoyiannis DP, Vartivarian S, Kantarjian HM, O'Brien S, Giralt SA, Andersson BS, Karl C, Champlin RE, Bodey GP. Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304. Clin Infect Dis. 1993 Dec; 17(6):1022-31. PMID: 8110925.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    305. Dimopoulos MA, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, Mehra R, van Besien K, Delasalle KB, Reading C, et al. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood. 1993 Oct 15; 82(8):2324-8. PMID: 8104539.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    306. Lomsky M, Waagstein F, Andersson B. The link between acute haemodynamic adrenergic beta-blockade and long-term effects in patients with heart failure. A study on diastolic function, heart rate and myocardial metabolism following intravenous metoprolol. Eur Heart J. 1993 Oct; 14(10):1375-85. PMID: 8262085.
      Citations: 11     Fields:    Translation:Humans
    307. Giralt S, Escudier S, Kantarjian H, Deisseroth A, Freireich EJ, Andersson BS, O'Brien S, Andreeff M, Fisher H, Cork A, et al. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med. 1993 Sep 09; 329(11):757-61. PMID: 7688862.
      Citations: 7     Fields:    Translation:Humans
    308. Waagstein F, Andersson B. Spectrum and outcome of congestive heart failure in a hospitalized population. Am Heart J. 1993 Sep; 126(3 Pt 1):632-40. PMID: 8362719.
      Citations: 13     Fields:    Translation:Humans
    309. Beran M, Pisa P, O'Brien S, Kurzrock R, Siciliano M, Cork A, Andersson BS, Kohli V, Kantarjian H. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res. 1993 Aug 01; 53(15):3603-10. PMID: 8339266.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    310. Ippoliti C, Przepiorka D, Smith T, Maiese S, Giralt S, Andersson BS, Deisseroth AB, Champlin RE. Adverse effects of molgramostim in marrow transplant recipients. Clin Pharm. 1993 Jul; 12(7):520-5. PMID: 8354039.
      Citations: 3     Fields:    Translation:Humans
    311. Giralt SA, Kantarjian HM, Talpaz M, Rios MB, Del Giglio A, Andersson BS, Przepiorka D, Deisseroth AB, Champlin RE. Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol. 1993 Jun; 11(6):1055-61. PMID: 8501491.
      Citations:    Fields:    Translation:Humans
    312. Andersson B, Ying JH, Lewis DE, Gibbs RA. Rapid characterization of HIV-1 sequence diversity using denaturing gradient gel electrophoresis and direct automated DNA sequencing of PCR products. PCR Methods Appl. 1993 May; 2(4):293-300. PMID: 8324502.
      Citations: 2     Fields:    Translation:HumansCells
    313. Deisseroth AB, Kantarjian H, Talpaz M, Champlin R, Reading C, Andersson B, Claxton D. Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery after preparative therapy. The University of Texas M.D. Anderson Cancer Center. Division of Medicine. Hum Gene Ther. 1993 Feb; 4(1):71-85. PMID: 8461383.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    314. Liu J, Campbell M, Guo JQ, Lu D, Xian YM, Andersson BS, Arlinghaus RB. BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon. Oncogene. 1993 Jan; 8(1):101-9. PMID: 8423987.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    315. Ippoliti C, Przepiorka D, Giralt S, Andersson BS, Wallerstein RO, Gutterman J, Deisseroth AB, Champlin RE. Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant. 1993 Jan; 11(1):55-9. PMID: 8094309.
      Citations: 1     Fields:    Translation:HumansCells
    316. Yau JC, LeMaistre CF, Andersson BS, Huan SD, Wallerstein RO, Woo SY, Spitzer G, Spinolo JA, Spencer V, Brunner LJ, et al. Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation. Am J Hematol. 1992 Sep; 41(1):40-4. PMID: 1503097.
      Citations: 4     Fields:    Translation:Humans
    317. Lyttkens K, Andersson B, Kehler M, Lindberg L. Bedside chest radiography using digital luminescence. A comparison between digital radiographs reviewed on a personal computer and as hard-copies. Acta Radiol. 1992 Sep; 33(5):427-30. PMID: 1389649.
      Citations: 2     Fields:    Translation:HumansAnimals
    318. Hovig E, Andersson B, Smith-S?rensen B, B?rresen AL. Screening for mutations in human HPRT cDNA using the polymerase chain reaction (PCR) in combination with constant denaturant gel electrophoresis (CDGE). Mutat Res. 1992 Sep; 269(1):41-53. PMID: 1381470.
      Citations: 2     Fields:    Translation:HumansCells
    319. Claxton DF, Reading CL, Nagarajan L, Tsujimoto Y, Andersson BS, Estey E, Cork A, Huh YO, Trujillo J, Deisseroth AB. Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. Blood. 1992 Aug 01; 80(3):582-6. PMID: 1353379.
      Citations: 5     Fields:    Translation:HumansCells
    320. Huan SD, Hester J, Spitzer G, Yau JC, Dunphy FR, Wallerstein RO, Dicke K, Spencer V, LeMaistre CF, Andersson BS, et al. Influence of mobilized peripheral blood cells on the hematopoietic recovery by autologous marrow and recombinant human granulocyte-macrophage colony-stimulating factor after high-dose cyclophosphamide, etoposide, and cisplatin. Blood. 1992 Jun 15; 79(12):3388-93. PMID: 1596578.
      Citations: 1     Fields:    Translation:Humans
    321. Wahren M, Andersson B, Ringertz NR, Pettersson I, Rud?n U. Identification of antigenic regions of the human Ro 60 kDa protein using recombinant antigen and synthetic peptides. J Autoimmun. 1992 Jun; 5(3):319-32. PMID: 1382431.
      Citations: 10     Fields:    Translation:HumansCells
    322. Aguilar-Santelises M, Loftenius A, Ljungh C, Svenson SB, Andersson B, Mellstedt H, Jondal M. Serum levels of helper factors (IL-1 alpha, IL-1 beta and IL-6), T-cell products (sCD4 and sCD8), sIL-2R and beta 2-microglobulin in patients with B-CLL and benign B lymphocytosis. Leuk Res. 1992 Jun-Jul; 16(6-7):607-13. PMID: 1386130.
      Citations: 4     Fields:    Translation:HumansCells
    323. Andersson BS, Bergerheim US, Collins VP, Childs C, Beran M, Sen S, Arden K, Pathak S, Siciliano MJ, Ost A, et al. KBM-3, an in vitro model of human acute myelomonocytic leukemia. Exp Hematol. 1992 Mar; 20(3):361-7. PMID: 1568450.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    324. Grimfors G, Andersson B, Tullgren O, Giscombe R, Holm G, Johansson B, Bj?rkholm M. Increased serum CD8 soluble antigen level is associated with blood lymphocyte abnormalities and other established indicators of a poor prognosis in adult Hodgkin's disease. Br J Haematol. 1992 Feb; 80(2):166-71. PMID: 1550771.
      Citations: 3     Fields:    Translation:HumansCells
    325. Andersson B, Hou SM, Lambert B. Mutations causing defective splicing in the human hprt gene. Environ Mol Mutagen. 1992; 20(2):89-95. PMID: 1380458.
      Citations: 5     Fields:    Translation:HumansCells
    326. Champlin R, Giralt S, Przepiorka D, Ho W, Lee K, Gajewski J, Nimer S, Andersson B, Wallerstein R, Ippolito C, et al. Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus leukemia. Prog Clin Biol Res. 1992; 377:385-94; discussion 395-8. PMID: 1438435.
      Citations: 3     Fields:    Translation:HumansCells
    327. Yau JC, Dimopoulos MA, Huan SD, Spencer V, Woo SY, Spitzer G, Brunner LJ, Wallerstein RO, Deisseroth AB, Andersson BS, et al. An effective acute graft-vs.-host disease prophylaxis with minidose methotrexate, cyclosporine, and single-dose methylprednisolone. Am J Hematol. 1991 Dec; 38(4):288-92. PMID: 1746537.
      Citations: 2     Fields:    Translation:Humans
    328. Elinder G, Hansson M, Andersson B, Andersson U, Henter JI, S?der O. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood. 1991 Dec 01; 78(11):2918-22. PMID: 1954380.
      Citations: 120     Fields:    Translation:Humans
    329. Yau JC, Dimopoulos MA, Huan SD, Tarrand JJ, Spencer V, Spitzer G, Meneghetti CM, Wallerstein RO, Andersson BS, LeMaistre CF. Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation. Eur J Haematol. 1991 Nov; 47(5):371-6. PMID: 1662140.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    330. Huan SD, Yau JC, Dunphy FR, Wallerstein RO, Dicke K, Spencer V, LeMaistre CF, Deisseroth AB, Hortobagyi GN, Holmes FA, et al. Impact of autologous bone marrow infusion on hematopoietic recovery after high-dose cyclophosphamide, etoposide, and cisplatin. J Clin Oncol. 1991 Sep; 9(9):1609-17. PMID: 1875221.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    331. Aguilar-Santelises M, Magnusson R, Svenson SB, Loftenius A, Andersson B, Mellstedt H, Jondal M. Expression of interleukin-1 alpha, interleukin-1 beta and interleukin-6 in chronic B lymphocytic leukaemia (B-CLL) cells from patients at different stages of disease progression. Clin Exp Immunol. 1991 Jun; 84(3):422-8. PMID: 2044220; PMCID: PMC1535440.
      Citations: 5     Fields:    Translation:Humans
    332. Farquhar D, Newman RA, Zuckerman JE, Andersson BS. Doxorubicin analogues incorporating chemically reactive substituents. J Med Chem. 1991 Feb; 34(2):561-4. PMID: 1995877.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    333. Claxton D, Suh SP, Filaccio M, Ellerson D, Gaozza E, Andersson B, Brenner M, Reading C, Feinberg A, Moen R, et al. Molecular analysis of retroviral transduction in chronic myelogenous leukemia. Hum Gene Ther. 1991; 2(4):317-21. PMID: 1665348.
      Citations: 1     Fields:    Translation:HumansCells
    334. Wahlin A, Andersson BS. Life table analysis for estimation of duration of aplasia after high-dose chemotherapy. Eur J Haematol. 1990 Nov; 45(5):284-5. PMID: 2261960.
      Citations:    Fields:    Translation:Humans
    335. Rundgren M, Harder S, Nelson SD, Andersson BS. Oxidant-induced changes in the cellular energy homeostasis. A study with 3,5-dimethyl N-acetyl-p-benzoquinone imine and isolated hepatocytes. Biochem Pharmacol. 1990 Jul 15; 40(2):239-43. PMID: 2375766.
      Citations:    Fields:    Translation:Animals
    336. Andersson BS, Wang YQ, McCredie KB, Farquhar D. Suitability of a new stable acetal analogue of aldoifosphamide for purging leukemic cells from human bone marrow. Leukemia. 1990 Jun; 4(6):435-40. PMID: 2359343.
      Citations:    Fields:    Translation:HumansCells
    337. Andersson BS, Luna MA, Yee C, Hui KK, Keating MJ, McCredie KB. Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia. Cancer. 1990 Mar 01; 65(5):1079-84. PMID: 2302659.
      Citations: 5     Fields:    Translation:Humans
    338. Malmstr?m U, Busch C, Norlen BJ, Andersson B. Influence of blood group type on prognosis of transitional cell carcinoma of the urinary bladder. Eur Urol. 1990; 18(2):97-100. PMID: 2226592.
      Citations:    Fields:    Translation:Humans
    339. Skinner WL, Murray D, Kohli V, Beran M, McCredie KB, Freireich EJ, Andersson BS. Resistance to 4-(9-acridinylamino) methanesulphon-m-anisidide (m-AMSA) in human myeloid leukaemia. Br J Cancer. 1990 Jan; 61(1):51-5. PMID: 2297490; PMCID: PMC1971335.
      Citations:    Fields:    Translation:HumansCells
    340. Ling YH, Andersson BS, Nelson JA. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells. Cancer Biochem Biophys. 1990 Jan; 11(1):23-30. PMID: 2159843.
      Citations: 5     Fields:    Translation:HumansCells
    341. Dreizen S, McCredie KB, Keating MJ, Andersson BS. Nutritional deficiencies in patients receiving cancer chemotherapy. Postgrad Med. 1990 Jan; 87(1):163-7, 170. PMID: 2296564.
      Citations: 14     Fields:    Translation:Humans
    342. Childs CC, Hirsch-Ginsberg C, Walters RS, Andersson BS, Reuben J, Trujillo JM, Cork A, Stass SA, Freireich EJ, Zipf TF. Myeloid surface antigen-positive acute lymphoblastic leukemia (My+ ALL): immunophenotypic, ultrastructural, cytogenetic, and molecular characteristics. Leukemia. 1989 Nov; 3(11):777-83. PMID: 2811478.
      Citations: 9     Fields:    Translation:Humans
    343. Kehler M, Albrechtsson U, Andersson B, Lundin A, Pettersson H, L?rusd?ttir H. Assessment of digital chest radiography using stimulable phosphor. Acta Radiol. 1989 Nov-Dec; 30(6):581-6. PMID: 2698744.
      Citations: 2     Fields:    Translation:Humans
    344. Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol. 1989 Aug; 7(8):1071-80. PMID: 2666590.
      Citations: 20     Fields:    Translation:Humans
    345. Dreizen S, McCredie KB, Keating MJ, Andersson BS, Schachner JR. Leukemia-associated skin infiltrates. Postgrad Med. 1989 Feb 01; 85(2):45-50, 53. PMID: 2915961.
      Citations:    Fields:    Translation:Humans
    346. Romero P, Beran M, Shtalrid M, Andersson B, Talpaz M, Blick M. Alternative 5' end of the bcr-abl transcript in chronic myelogenous leukemia. Oncogene. 1989 Jan; 4(1):93-8. PMID: 2915904.
      Citations: 3     Fields:    Translation:HumansCells
    347. Hittelman WN, Agbor P, Petkovic I, Andersson B, Kantarjian H, Walters R, Koller C, Beran M. Detection of leukemic clone maturation in vivo by premature chromosome condensation. Blood. 1988 Dec; 72(6):1950-60. PMID: 3196873.
      Citations: 1     Fields:    Translation:HumansCells
    348. Eisbruch A, Blick M, Evinger-Hodges MJ, Beran M, Andersson B, Gutterman JU, Kurzrock R. Effect of differentiation-inducing agents on oncogene expression in a chronic myelogenous leukemia cell line. Cancer. 1988 Sep 15; 62(6):1171-8. PMID: 3044574.
      Citations: 8     Fields:    Translation:HumansCells
    349. Walters RS, Kantarjian HM, Keating MJ, Plunkett WK, Estey EH, Andersson B, Beran M, McCredie KB, Freireich EJ. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer. 1988 Aug 15; 62(4):677-82. PMID: 3165047.
      Citations: 9     Fields:    Translation:Humans
    350. Kantarjian HM, Walters RS, Keating MJ, Talpaz M, Andersson B, Beran M, McCredie KB, Freireich EJ. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer. 1988 Aug 15; 62(4):672-6. PMID: 3165046.
      Citations: 6     Fields:    Translation:Humans
    351. Beran M, Andersson BS, Wang Y, McCredie KB, Farquhar D. The effects of acetaldophosphamide, a novel stable aldophosphamide analogue, on normal human and leukemic progenitor cells in vitro: implications for use in bone marrow purging. Cancer Res. 1988 Jan 15; 48(2):339-45. PMID: 3275495.
      Citations:    Fields:    Translation:HumansCells
    352. LeMaistre A, Childs CC, Hirsch-Ginsberg C, Reuben J, Cork A, Trujillo JM, Andersson B, McCredie KB, Freireich E, Stass SA. Heterogeneity in acute undifferentiated leukemia. Hematol Pathol. 1988; 2(2):79-90. PMID: 3198552.
      Citations: 2     Fields:    Translation:HumansCells
    353. Beran M, O'Brien S, Andersson B, McCredie KB, Gutterman JU. Tumor necrosis factor and human hematopoiesis: II. Inhibition and mode of action on normal and chronic myelogenous leukemia-derived granulocyte-macrophage progenitor cells. Hematol Pathol. 1988; 2(2):65-71. PMID: 3143710.
      Citations:    Fields:    Translation:HumansCells
    354. Bakic M, Chan D, Andersson BS, Beran M, Silberman L, Estey E, Ricketts L, Zwelling LA. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells. Biochem Pharmacol. 1987 Dec 01; 36(23):4067-77. PMID: 2825713.
      Citations: 1     Fields:    Translation:HumansCells
    355. Beran M, Zander AR, Andersson BS, McCredie KB. Regrowth of granulocyte-macrophage progenitor cells (GM-CFC) in suspension cultures of bone marrow depleted of GM-CFC with 4-hydroperoxycyclophosphamide (4-HC). Eur J Haematol. 1987 Aug; 39(2):118-24. PMID: 3666100.
      Citations:    Fields:    Translation:HumansCells
    356. Blick M, Romero P, Talpaz M, Kurzrock R, Shtalrid M, Andersson B, Trujillo J, Beran M, Gutterman J. Molecular characteristics of chronic myelogenous leukemia in blast crisis. Cancer Genet Cytogenet. 1987 Aug; 27(2):349-56. PMID: 3474057.
      Citations: 5     Fields:    Translation:HumansCells
    357. Estey EH, Silberman L, Beran M, Andersson BS, Zwelling LA. The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs. Biochem Biophys Res Commun. 1987 Apr 29; 144(2):787-93. PMID: 3034264.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    358. Aw TY, Andersson BS, Jones DP. Suppression of mitochondrial respiratory function after short-term anoxia. Am J Physiol. 1987 Apr; 252(4 Pt 1):C362-8. PMID: 2882683.
      Citations: 7     Fields:    Translation:AnimalsCells
    359. Andersson BS, Aw TY, Jones DP. Mitochondrial transmembrane potential and pH gradient during anoxia. Am J Physiol. 1987 Apr; 252(4 Pt 1):C349-55. PMID: 3565555.
      Citations: 38     Fields:    Translation:AnimalsCells
    360. Aw TY, Andersson BS, Jones DP. Mitochondrial transmembrane ion distribution during anoxia. Am J Physiol. 1987 Apr; 252(4 Pt 1):C356-61. PMID: 3565556.
      Citations: 15     Fields:    Translation:AnimalsCells
    361. Beran M, Andersson BS. Development and characterization of a human myelogenous leukemia cell line resistant to 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide. Cancer Res. 1987 Apr 01; 47(7):1897-904. PMID: 3469023.
      Citations: 5     Fields:    Translation:Cells
    362. Beran M, Andersson BS, Kelleher P, Whalen K, McCredie K, Gutterman J. Diversity of the effect of recombinant tumor necrosis factors alpha and beta on human myelogenous leukemia cell lines. Blood. 1987 Mar; 69(3):721-6. PMID: 3028534.
      Citations: 1     Fields:    Translation:HumansCells
    363. Andersson BS, Beran M, Bakic M, Silberman LE, Newman RA, Zwelling LA. In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia. Cancer Res. 1987 Feb 15; 47(4):1040-4. PMID: 3026621.
      Citations: 13     Fields:    Translation:HumansCells
    364. Andersson BS, Beran M, Pathak S, Goodacre A, Barlogie B, McCredie KB. Ph-positive chronic myeloid leukemia with near-haploid conversion in vivo and establishment of a continuously growing cell line with similar cytogenetic pattern. Cancer Genet Cytogenet. 1987 Feb; 24(2):335-43. PMID: 3466682.
      Citations: 17     Fields:    Translation:HumansCells
    365. Andersson BS, Beran M, Stuckey SE, McCredie KB, Mavligit GM. Sensitivity and resistance to chemotherapy in acute leukemia: correlation with in vitro drug uptake and lack of potentiation by verapamil. Med Oncol Tumor Pharmacother. 1987; 4(1):17-21. PMID: 3600053.
      Citations:    Fields:    Translation:HumansCells
    366. Beran M, Andersson B, Kantarjian H, Keating M, Rios A, McCredie KB, Freireich EJ, Gutterman J. Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferon. Leukemia. 1987 Jan; 1(1):52-7. PMID: 2444829.
      Citations: 3     Fields:    Translation:HumansCells
    367. Andersson BS, Luna MA, McCredie KB. Systemic aspergillosis as cause of myocardial infarction. Cancer. 1986 Nov 01; 58(9):2146-50. PMID: 3756830.
      Citations: 2     Fields:    Translation:Humans
    368. Wassermann K, Zwelling LA, Mullins TD, Silberman LE, Andersson BS, Bakic M, Acton EM, Newman RA. Effects of 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin and doxorubicin on the survival, DNA integrity, and nucleolar morphology of human leukemia cells in vitro. Cancer Res. 1986 Aug; 46(8):4041-6. PMID: 3731072.
      Citations: 3     Fields:    Translation:HumansCells
    369. Odaimi M, Andersson BS, McCredie KB, Beran M. Drug sensitivity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia. Cancer Res. 1986 Jul; 46(7):3330-3. PMID: 3754787.
      Citations: 5     Fields:    Translation:HumansCells
    370. Andersson BS, Beran M, Barlogie B, Van NT, McCredie KB. Analysis of nuclear m-AMSA content by DNA fluorochrome competition. Eur J Cancer Clin Oncol. 1986 Jul; 22(7):883-9. PMID: 3464432.
      Citations: 2     Fields:    Translation:HumansCells
    371. Bakic M, Beran M, Andersson BS, Silberman L, Estey E, Zwelling LA. The production of topoisomerase II-mediated DNA cleavage in human leukemia cells predicts their susceptibility to 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA). Biochem Biophys Res Commun. 1986 Jan 29; 134(2):638-45. PMID: 3004458.
      Citations: 6     Fields:    Translation:HumansCells
    372. Adams F, Fernandez F, Andersson BS. Emergency pharmacotherapy of delirium in the critically ill cancer patient. Psychosomatics. 1986 Jan; 27(1 Suppl):33-8. PMID: 3952253.
      Citations: 9     Fields:    Translation:HumansPHPublic Health
    373. Hellman B, Andersson BS, Slanina P, Mohammed A, Brandt I, Beran M. The tissue localization of m-AMSA and its effect on thymidine incorporation in various tissues in vivo. Med Oncol Tumor Pharmacother. 1986; 3(2):87-94. PMID: 3755785.
      Citations:    Fields:    Translation:AnimalsCells
    374. Beran M, Hittelman WN, Andersson BS, McCredie KB. Induction of differentiation in human myeloid leukemia cells with cytosine arabinoside. Leuk Res. 1986; 10(8):1033-9. PMID: 3462437.
      Citations: 1     Fields:    Translation:HumansCells
    375. Blick MB, Andersson BS, Gutterman JU, Keating A, Beran M. The c-abl, bcr and C lambda genes are amplified in a cell line but not in the uncultured cells from a patient with chronic myelogenous leukemia. Leuk Res. 1986; 10(12):1401-9. PMID: 3099097.
      Citations:    Fields:    Translation:HumansCells
    376. Andersson BS, Cogan BM, Keating MJ, Estey EH, McCredie KB, Freireich EJ. Subacute pulmonary failure complicating therapy with high-dose Ara-C in acute leukemia. Cancer. 1985 Nov 01; 56(9):2181-4. PMID: 4052964.
      Citations: 11     Fields:    Translation:Humans
    377. Keating MJ, Estey E, Plunkett W, Iacoboni S, Walters R, Kantarjian H, Andersson B, Beran M, McCredie KB, Freireich EJ. Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. Semin Oncol. 1985 Jun; 12(2 Suppl 3):98-104. PMID: 3859935.
      Citations: 1     Fields:    Translation:Humans
    378. Andersson BS, Jones DP. Use of digitonin fractionation to determine mitochondrial transmembrane ion distribution in cells during anoxia. Anal Biochem. 1985 Apr; 146(1):164-72. PMID: 3993928.
      Citations: 13     Fields:    Translation:AnimalsCells
    379. Ross D, Larsson R, Andersson B, Nilsson U, Lindquist T, Lindeke B, Mold?us P. The oxidation of p-phenetidine by horseradish peroxidase and prostaglandin synthase and the fate of glutathione during such oxidations. Biochem Pharmacol. 1985 Feb 01; 34(3):343-51. PMID: 2982385.
      Citations: 3     Fields:    Translation:Cells
    380. Andersson BS, Adams F, McCredie KB. High-dose neuroleptics for acute brain failure after intensive chemotherapy for acute leukemia. Acta Psychiatr Scand. 1984 Sep; 70(3):193-7. PMID: 6149668.
      Citations:    Fields:    Translation:Humans
    381. Lindsten T, Thompson CB, Finkelman FD, Andersson B, Scher I. Changes in the expression of B cell surface markers on complement receptor-positive and complement receptor-negative B cells induced by phorbol myristate acetate. J Immunol. 1984 Jan; 132(1):235-9. PMID: 6361121.
      Citations: 2     Fields:    Translation:AnimalsCells
    382. Andersson B, Larsson R, Rahimtula A, Mold?us P. Hydroperoxide-dependent activation of p-phenetidine catalyzed by prostaglandin synthase and other peroxidases. Biochem Pharmacol. 1983 Mar 15; 32(6):1045-50. PMID: 6404283.
      Citations:    Fields:    Translation:HumansAnimalsCells
    383. Andersson B, Collins VP. Post mortem, ultrastructural cardiac muscle changes and anthracycline toxicity. Biomed Pharmacother. 1983; 37(6):281-7. PMID: 6367847.
      Citations:    Fields:    Translation:AnimalsCells
    384. Hansson M, Beran M, Andersson B, Kiessling R. Inhibition of in vitro granulopoiesis by autologous allogeneic human NK cells. J Immunol. 1982 Jul; 129(1):126-32. PMID: 6177746.
      Citations: 31     Fields:    Translation:HumansCells
    385. Berggren PO, Andersson B, Hellman B. Stimulation of the insulin secretory mechanism following barium accumulation in pancreatic beta-cells. Biochim Biophys Acta. 1982 Jun 08; 720(3):320-8. PMID: 6285995.
      Citations: 5     Fields:    Translation:AnimalsCells
    386. Andersson B, Rahimtula A, Berggren M, Mold?us P. Prostaglandin synthetase catalyzed activation of paracetamol. Biochem Pharmacol. 1982 Apr 01; 31(7):1363-8. PMID: 6807320.
      Citations: 2     Fields:    Translation:AnimalsCells
    387. Reizenstein P, Andersson B, Beran M. Possible mechanisms of immunotherapy action in acute nonlymphocytic leukemia: macrophage production of colony-stimulating activity. Recent Results Cancer Res. 1982; 80:64-9. PMID: 7036298.
      Citations:    Fields:    Translation:HumansCells
    388. Andersson B, Engstedt L, Gahrton G, Hast R, Holm G, Killander A, Lantz B, Lockner D, Mellstedt H, Palmblad J, Paul C, Peterson C, Simonsson B, Stalfelt AM, Wadman B, Oberg G, L?nnqvist B, Bj?rkholm M, Ud?n AM. Prednimustine and vincristine compared with cytosine arabinoside and thioguanine for treatment of elderly patients with acute nonlymphoblastic leukemia. Cancer Chemother Pharmacol. 1982; 9(2):89-92. PMID: 7172410.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    389. Andersson B, Beran M, Peterson C, Tribukait B. Significance of cellular pharmacokinetics for the cytotoxic effects of daunorubicin. Cancer Res. 1982 Jan; 42(1):178-83. PMID: 7053847.
      Citations: 11     Fields:    Translation:AnimalsCells
    390. Jones DP, Meyer DB, Andersson B, Orrenius S. Conversion of catalase to the secondary catalase-peroxide complex (compound II) by alpha-methyldopa. Mol Pharmacol. 1981 Jul; 20(1):159-64. PMID: 7290082.
      Citations: 2     Fields:    Translation:Animals
    391. Skoog L, Ost A, Andersson B, Hast R, Giannoulis N, Humla S, Reizenstein P, Nordenskj?ld B, H?gerstr?m T. Glucocorticoid receptor concentrations and terminal transferase activity as indicators of prognosis in acute non-lymphocytic leukaemia. Br Med J (Clin Res Ed). 1981 Jun 06; 282(6279):1826-9. PMID: 6263401; PMCID: PMC1506447.
      Citations: 5     Fields:    Translation:HumansCells
    392. Ter?nt A, Andersson B. The prognosis for patients with cerebrovascular stroke and transient ischemic attacks. Ups J Med Sci. 1981; 86(1):63-74. PMID: 7303332.
      Citations: 4     Fields:    Translation:Humans
    393. Andersson B, Beran M, Peterson C, Alv?n G. Differences in the plasma kinetics of daunorubicin in normal and leukemic rats. Acta Radiol Oncol. 1981; 20(5):325-8. PMID: 6278852.
      Citations: 1     Fields:    Translation:AnimalsCells
    394. Nilsson SO, Andersson B, Eksborg S, Beran M, Ehrsson H. Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients. Cancer Chemother Pharmacol. 1981; 5(4):261-6. PMID: 7261253.
      Citations: 2     Fields:    Translation:Humans
    395. Andersson B, Norling A, Ormstad K, Mold?us P. Effect of chronic ethanol administration on drug metabolism in isolated hepatocytes with emphasis on paracetamol activation. Biochem Pharmacol. 1980 Jun 15; 29(12):1741-5. PMID: 7190825.
      Citations: 8     Fields:    Translation:HumansAnimals
    396. Hansson M, Kiessling R, Andersson B, Roder J, Gr?nberg A, K?rre K. Demonstration of natural antibodies in normal rabbit serum with similar specificity pattern as mouse natural killer cells. J Natl Cancer Inst. 1980 May; 64(5):1113-9. PMID: 6966004.
      Citations: 4     Fields:    Translation:AnimalsCells
    397. Andersson B, Beran M. Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex. Cancer Chemother Pharmacol. 1980; 4(3):205-7. PMID: 7397945.
      Citations: 4     Fields:    Translation:HumansCells
    398. Skoog L, Ost A, Andersson B, Hast R, Giannoulis N, Reitzenstein P, Nordenskj?ld B. Biochemical markers as indicators of prognosis in acute nonlymphocytic leukemia (ANLL). Adv Enzyme Regul. 1980; 19:287-93. PMID: 6278867.
      Citations:    Fields:    Translation:Humans
    399. Andersson B, Jones DP, Orrenius S. Effect of calcium ions on ethanol oxidation and drug glucuronidation in isolated hepatocytes. Biochem J. 1979 Dec 15; 184(3):709-11. PMID: 540060; PMCID: PMC1161859.
      Citations: 1     Fields:    Translation:AnimalsCells
    400. Dallanis T, Klein G, Andersson B. Selection of a low antigenic variant subline from the TA3St ascites carcinoma by repeated passage of antibody-coated cells through anti-immunoglobulin columns. J Natl Cancer Inst. 1979 Aug; 63(2):383-8. PMID: 379399.
      Citations:    Fields:    Translation:AnimalsCells
    401. Andersson B, Andersson I, Beran M, Ehrsson H, Eksborg S. Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex. Cancer Chemother Pharmacol. 1979; 2(1):15-7. PMID: 498413.
      Citations: 7     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    402. Andersson B, Beran M, Eberhardsson B, Eksborg S, Slanina P. Uptake and distribution of daunorubicin and daunorubicin-DNA complex in mice as studied by whole-body autoradiography and liquid chromatography. Cancer Chemother Pharmacol. 1979; 2(3):159-67. PMID: 110487.
      Citations: 3     Fields:    Translation:Animals
    403. Beran M, Andersson B, Eksborg S, Ehrsson H. Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex. Cancer Chemother Pharmacol. 1979; 2(1):19-24. PMID: 498414.
      Citations: 7     Fields:    Translation:HumansCells
    404. Jones DP, Thor H, Andersson B, Orrenius S. Detoxification reactions in isolated hepatocytes. Role of glutathione peroxidase, catalase, and formaldehyde dehydrogenase in reactions relating to N-demethylation by the cytochrome P-450 system. J Biol Chem. 1978 Sep 10; 253(17):6031-7. PMID: 567217.
      Citations: 19     Fields:    Translation:AnimalsCells
    405. Eksborg S, Ehrsson H, Andersson B, Beran M. Liquid chromatographic determination of daunorubicin and daunorubicinol in plasma from leukemic patients. J Chromatogr. 1978 Jun 01; 153(1):211-8. PMID: 659557.
      Citations: 12     Fields:    
    406. Andersson B, Norling A, Mold?us P. Interaction of ethanol oxidation with glucuronidation in isolated hepatocytes. Biochem Pharmacol. 1978; 27(22):2583-8. PMID: 215162.
      Citations: 8     Fields:    Translation:AnimalsCells
    407. Svenson A, Andersson B. The application of cyanide-metabolizing enzymes to environmental control. I. Preparation and characterization of rhodanese and beta-cyanoalanine synthase, immobilized on solid supports. Anal Biochem. 1977 Dec; 83(2):739-45. PMID: 603055.
      Citations:    Fields:    Translation:Animals
    408. Lamon EW, Whitten HD, Skurzak HM, Andersson B, Lidin B. IgM antibody-dependent cell-mediated cytotoxicity in the Moloney sarcoma virus system: the involvement of T and B lymphocytes as effector cells. J Immunol. 1975 Nov; 115(5):1288-94. PMID: 1080777.
      Citations: 15     Fields:    Translation:AnimalsCells
    409. Blomgren H, Andersson B. Cross-reactivity patterns of mouse lymphocytes sensitized against the major histocompatibility complex using a graft-versus-host assay. Cell Immunol. 1974 Mar 30; 11(1-3):122-9. PMID: 4156191.
      Citations:    Fields:    Translation:AnimalsCellsPHPublic Health
    410. Schirrmacher V, Rubin B, Golstein P, Wigzell H, Andersson B. Cytotoxic immune cells with specificity for defined soluble antigens. 3. Separation from helper cells and from antibody-forming cell precursors. Transplant Proc. 1973 Dec; 5(4):1447-50. PMID: 4544162.
      Citations: 3     Fields:    Translation:AnimalsCells
    411. Blomgren H, Andersson B. Loss of graft-versus-host reactivity of mouse lymphocytes during serial passage through irradiated allogeneic hosts. Cell Immunol. 1973 Oct; 9(1):76-83. PMID: 4147543.
      Citations: 1     Fields:    Translation:AnimalsCells
    412. Blomgren H, Andersson B. Inhibition of erythropoiesis in the spleens of irradiated mice injected with allogeneic lymphocytes. Reactivity of lymphocytes aganist non-H-2 transplantation antigens. Cell Immunol. 1973 Jun; 7(3):453-8. PMID: 4146281.
      Citations:    Fields:    Translation:AnimalsCells
    413. Blomgren H, Andersson B. Inhibition of erythroid cell growth in irradiated mice by allogeneic lymphoid cells: a quantitative method for graft-versus-host-reactivity of lymphoid cells. Cell Immunol. 1972 Feb; 3(2):318-25. PMID: 4400933.
      Citations: 3     Fields:    Translation:AnimalsCells
    414. Ioachim HL, Sabbath M, Andersson B, Keller S. Viral and chemical leukemia in the rat: comparative study. J Natl Cancer Inst. 1971 Jul; 47(1):161-77. PMID: 4936573.
      Citations: 3     Fields:    Translation:AnimalsCells
    415. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplantation.
    416. Fludarabine (famp)-based chemotherapy at conventional doses allows engraftment of allogeneic (allo) peripheral blood progenitor cell (pbpc) transplantation in chronic lymphocytic leukemia (cll). Experimental Hematology. 24:1046.
    417. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biology of Blood and Marrow Transplantation. 21:1914-1920.
    418. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biology of Blood and Marrow Transplantation. 22:961-965.
    419. Antiproliferative effect of recombinant alpha (rIFN-α) and gamma (rIFN-γ) interferons in myelogenous leukemia cell lines.
    420. Erratum. Chromatographia. 71:353.
    421. Development of a second Philadelphia (Ph1) chromosome in chronic myelogenous leukemia (CML) is characterized by a single aberrant overexpressed 8 kb c-abl transcript and the loss of the normal c-abl transcripts.
    422. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 128:297-312.
    423. Analysis of anthraquinone glycosides - handling of blood samples. Acta Pharmaceutica Suecica. 15:462.
    424. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget. 7:63829-63838.
    425. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leukemia and Lymphoma. 55:1625-1634.
    426. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas. Experimental Hematology.
    427. Chemopurging of leukemic marrow in conjunction with autologous bone marrow transplantation. Cancer Bulletin. 42:185-193.
    428. Differences in the plasma kinetics of daunorubicin in normal and leukemic rats. Acta Oncologica. 20:325-328.
    429. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation. 23:285-292.
    430. Chromatographic assay for amsacrine (AMSA) in plasma and leukemic cell extracts.
    431. Allogeneic transplantation with nonmyeloablative or reduced intensity conditioning. Blood. 96.
    432. Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. American Journal of Transplantation.
    433. Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors. Bone Marrow Transplantation.
    434. Pharmacologic Basis for High-dose Chemotherapy. 211-224.
    435. Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. Leukemia and Lymphoma. 1-9.
    436. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica. 102:110-117.
    437. Biologically-cleavable phosphate protective groups. Tetrahedron Letters. 36:655-658.
    438. Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transplant Infectious Disease.
    439. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival forPatients with Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation.
    440. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. Leukemia Research. 47:100-108.
    441. Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference. Leukemia and Lymphoma. 1-5.
    442. Clinical resistance and sensitivity to chemotherapy in human acute leukemia.
    443. Quantitative determination of busulfan in human plasma by UPLC. Chromatographia. 70:1505-1510.
    444. New directions in the biology and therapy of chronic myeloid leukemia. Leukemia and Lymphoma. 6:89-95.
    445. Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect?. Bone Marrow Transplantation.
    446. Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines. Blood Cancer Journal. 4.
    447. Biology of Blood and Marrow Transplantation. 22:1792-1800.
    448. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation. 21:1948-1954.
    449. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes. Biology of Blood and Marrow Transplantation.
    450. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation. 22:1218-1226.
    ANDERSSON's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (1271)
    Explore
    _
    Co-Authors (117)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _